Current awareness: Pharmacoepidemiology and drug safety
Identifieur interne : 000830 ( Istex/Corpus ); précédent : 000829; suivant : 000831Current awareness: Pharmacoepidemiology and drug safety
Auteurs :Source :
- Pharmacoepidemiology and Drug Safety [ 1053-8569 ] ; 2009-08.
English descriptors
- Teeft :
- Acta, Adverse drug reactions, Allergy, Arthritis rheum, Asthma, Bevacizumab, Bisphosphonate, Breast cancer patients, Canc, Cardiovascular, Clin, Clin pharmacol, Clin psychiatry, Coll, Copyright, Current awareness, Dept, Dept dermatol, Dept neurol, Dept pediat, Dept psychiat, Dermatol, Drug safety, Epidemiol, Gastroenterol, Hematol, Hlth, Hosp, Immunol, Inhibitor, Inst, John wiley sons, Klin, Nephrol, Neurol, Nonsteroidal, Oncol, Ophthalmol, Osteonecrosis, Pediat, Pediatr, Pharm, Pharmacoepidemiol, Pharmacoepidemiol drug, Pharmacoepidemiology, Pharmacokinetics, Pharmacol, Pract, Predictor, Psychiat, Publ, Randomized, Renal, Rheumatol, Selective serotonin reuptake inhibitors, Serotonin, Serv, Stat methods, Surg, Toxicity, Univ, Univ pennsylvania, Univ texas, Yale univ.
Abstract
In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.
Url:
DOI: 10.1002/pds.1651
Links to Exploration step
ISTEX:D9DDB40CD540E03ED72C36319DCB2DB3F7123960Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current awareness: Pharmacoepidemiology and drug safety</title></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D9DDB40CD540E03ED72C36319DCB2DB3F7123960</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/pds.1651</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-Z4H8CGGW-Z/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000830</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000830</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title></analytic><monogr></monogr><series><title level="j" type="main">Pharmacoepidemiology and Drug Safety</title><title level="j" type="alt">PHARMACOEPIDEMIOLOGY AND DRUG SAFETY</title><idno type="ISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><imprint><biblScope unit="vol">18</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="i">i</biblScope><biblScope unit="page" to="x">x</biblScope><biblScope unit="page-count">10</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2009-08">2009-08</date></imprint><idno type="ISSN">1053-8569</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1053-8569</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acta</term><term>Adverse drug reactions</term><term>Allergy</term><term>Arthritis rheum</term><term>Asthma</term><term>Bevacizumab</term><term>Bisphosphonate</term><term>Breast cancer patients</term><term>Canc</term><term>Cardiovascular</term><term>Clin</term><term>Clin pharmacol</term><term>Clin psychiatry</term><term>Coll</term><term>Copyright</term><term>Current awareness</term><term>Dept</term><term>Dept dermatol</term><term>Dept neurol</term><term>Dept pediat</term><term>Dept psychiat</term><term>Dermatol</term><term>Drug safety</term><term>Epidemiol</term><term>Gastroenterol</term><term>Hematol</term><term>Hlth</term><term>Hosp</term><term>Immunol</term><term>Inhibitor</term><term>Inst</term><term>John wiley sons</term><term>Klin</term><term>Nephrol</term><term>Neurol</term><term>Nonsteroidal</term><term>Oncol</term><term>Ophthalmol</term><term>Osteonecrosis</term><term>Pediat</term><term>Pediatr</term><term>Pharm</term><term>Pharmacoepidemiol</term><term>Pharmacoepidemiol drug</term><term>Pharmacoepidemiology</term><term>Pharmacokinetics</term><term>Pharmacol</term><term>Pract</term><term>Predictor</term><term>Psychiat</term><term>Publ</term><term>Randomized</term><term>Renal</term><term>Rheumatol</term><term>Selective serotonin reuptake inhibitors</term><term>Serotonin</term><term>Serv</term><term>Stat methods</term><term>Surg</term><term>Toxicity</term><term>Univ</term><term>Univ pennsylvania</term><term>Univ texas</term><term>Yale univ</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>univ</json:string><json:string>clin</json:string><json:string>hosp</json:string><json:string>pharmacol</json:string><json:string>clin pharmacol</json:string><json:string>inst</json:string><json:string>pharmacoepidemiol</json:string><json:string>hlth</json:string><json:string>pharmacoepidemiol drug</json:string><json:string>dermatol</json:string><json:string>pharmacoepidemiology</json:string><json:string>oncol</json:string><json:string>pediat</json:string><json:string>serv</json:string><json:string>nephrol</json:string><json:string>drug safety</json:string><json:string>rheumatol</json:string><json:string>gastroenterol</json:string><json:string>epidemiol</json:string><json:string>pharm</json:string><json:string>dept</json:string><json:string>allergy</json:string><json:string>neurol</json:string><json:string>psychiat</json:string><json:string>toxicity</json:string><json:string>john wiley sons</json:string><json:string>coll</json:string><json:string>canc</json:string><json:string>copyright</json:string><json:string>predictor</json:string><json:string>pharmacokinetics</json:string><json:string>osteonecrosis</json:string><json:string>hematol</json:string><json:string>randomized</json:string><json:string>immunol</json:string><json:string>acta</json:string><json:string>surg</json:string><json:string>pediatr</json:string><json:string>klin</json:string><json:string>bisphosphonate</json:string><json:string>current awareness</json:string><json:string>pract</json:string><json:string>dept psychiat</json:string><json:string>adverse drug reactions</json:string><json:string>ophthalmol</json:string><json:string>bevacizumab</json:string><json:string>nonsteroidal</json:string><json:string>publ</json:string><json:string>serotonin</json:string><json:string>dept dermatol</json:string><json:string>stat methods</json:string><json:string>renal</json:string><json:string>dept pediat</json:string><json:string>breast cancer patients</json:string><json:string>yale univ</json:string><json:string>clin psychiatry</json:string><json:string>inhibitor</json:string><json:string>arthritis rheum</json:string><json:string>selective serotonin reuptake inhibitors</json:string><json:string>univ pennsylvania</json:string><json:string>dept neurol</json:string><json:string>univ texas</json:string><json:string>asthma</json:string><json:string>cardiovascular</json:string><json:string>birth defects</json:string><json:string>epidemiologic studies</json:string><json:string>clin colorectal cancer</json:string><json:string>aliment pharmacol</json:string><json:string>risk factors</json:string><json:string>side effects</json:string><json:string>leiden univ</json:string><json:string>mcgill univ</json:string><json:string>allergy asthma immunol</json:string><json:string>acta anaesthesiol scand</json:string><json:string>dept anesthesiol</json:string><json:string>anesth analg</json:string><json:string>acta ophthalmol scand</json:string><json:string>dept ophthalmol</json:string><json:string>rheumatoid arthritis</json:string><json:string>case report</json:string><json:string>dept pharmacol</json:string><json:string>dept nephrol</json:string><json:string>renal failure</json:string><json:string>systematic review</json:string><json:string>dermatol venereol</json:string><json:string>boston univ</json:string><json:string>adverse events</json:string><json:string>dept cardiol</json:string><json:string>dept clin pharmacol</json:string><json:string>univ copenhagen</json:string><json:string>psychiatry</json:string><json:string>syndrome</json:string><json:string>contrast agents</json:string><json:string>allergy clin immunol</json:string><json:string>arch dermatol</json:string><json:string>anesth reanim</json:string><json:string>oklahoma city</json:string><json:string>univ oklahoma hlth</json:string><json:string>silver spring</json:string><json:string>indian pediatr</json:string><json:string>antimicrob agents chemother</json:string><json:string>drug evaluation</json:string><json:string>risk factor</json:string><json:string>clin trials</json:string><json:string>drug reaction</json:string><json:string>india inst</json:string><json:string>gene variants</json:string><json:string>natl taiwan univ hosp</json:string><json:string>chung shan</json:string><json:string>peripheral neuropathy</json:string><json:string>brit columbia</json:string><json:string>depressive symptoms</json:string><json:string>hospital morbidity study</json:string><json:string>insufficient information</json:string><json:string>wien klin wochenschr</json:string><json:string>bursledon hall</json:string><json:string>blundell lane</json:string><json:string>monitoring study</json:string><json:string>washington univ</json:string><json:string>serv dermatol</json:string><json:string>propofol infusion electrocardiographic pattern</json:string><json:string>crit care</json:string><json:string>triangle park</json:string><json:string>dept epidemiol</json:string><json:string>publ hlth</json:string><json:string>harvard univ</json:string><json:string>dept pharm</json:string><json:string>clin epidemiol</json:string><json:string>dept gastroenterol</json:string><json:string>pediatr anaesth</json:string><json:string>dept gastroenterol hepatol</json:string><json:string>addenbrookes hosp</json:string><json:string>royal victoria hosp</json:string><json:string>coll publ hlth</json:string><json:string>gastrointestinal risks</json:string><json:string>nonsteroidal antiinflammatory drugs</json:string><json:string>american college</json:string><json:string>nonselective nonsteroidal antiinflammatory drugs</json:string><json:string>drug events</json:string><json:string>japanese patients</json:string><json:string>univ toronto</json:string><json:string>lactam allergy</json:string><json:string>joint bone spine</json:string><json:string>ankylosing spondylitis</json:string><json:string>camille desmoulins</json:string><json:string>brigham womens hosp</json:string><json:string>inst gustave roussy</json:string><json:string>safety profile</json:string><json:string>clinical trials</json:string><json:string>selective serotonin reuptake inhibitor</json:string><json:string>dose selection</json:string><json:string>oral contraceptives</json:string><json:string>psychopharmacol clin</json:string><json:string>antidepressant medications</json:string><json:string>safety assessment</json:string><json:string>dept clin expt</json:string><json:string>cardiff univ</json:string><json:string>wales dept psychol</json:string><json:string>hergest unit</json:string><json:string>gastroenterol hepatol</json:string><json:string>univ pittsburgh</json:string><json:string>bellefield towers</json:string><json:string>psychiatry clin pract</json:string><json:string>pharmacoepidemiol pharmacoecon</json:string><json:string>hotel dieu</json:string><json:string>hines blvd</json:string><json:string>univ pisa</json:string><json:string>hematol oncol</json:string><json:string>metroplex clin</json:string><json:string>peripher nerv syst</json:string><json:string>clin genitourin cancer</json:string><json:string>oncology basel</json:string><json:string>cell carcinoma</json:string><json:string>amedeo avogadro univ</json:string><json:string>anderson canc</json:string><json:string>dept obstet gynaecol</json:string><json:string>adverse reaction</json:string><json:string>clin pract</json:string><json:string>dental modalities</json:string><json:string>clinical efficacy</json:string><json:string>bisphosphonate osteonecrosis</json:string><json:string>clin oncol</json:string><json:string>radiother oncol</json:string><json:string>multiple myeloma</json:string><json:string>arch intern</json:string><json:string>inflamm bowel</json:string><json:string>inflammatory bowel disease</json:string><json:string>inhaled corticosteroids</json:string><json:string>slone epidemiol</json:string><json:string>ulcerative colitis</json:string><json:string>porte madeleine</json:string><json:string>efficacy</json:string><json:string>medication</json:string></teeft></keywords><articleId><json:string>PDS1651</json:string></articleId><arkIstex>ark:/67375/WNG-Z4H8CGGW-Z</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>bibliography</json:string></originalGenre><abstract>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</abstract><qualityIndicators><score>8.908</score><pdfWordCount>12576</pdfWordCount><pdfCharCount>76704</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>10</pdfPageCount><pdfPageSize>595 x 790.863 pts</pdfPageSize><pdfWordsPerPage>1258</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>159</abstractWordCount><abstractCharCount>1137</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Current awareness: Pharmacoepidemiology and drug safety</title><genre><json:string>other</json:string></genre><host><title>Pharmacoepidemiology and Drug Safety</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1099-1557</json:string></doi><issn><json:string>1053-8569</json:string></issn><eissn><json:string>1099-1557</json:string></eissn><publisherId><json:string>PDS</json:string></publisherId><volume>18</volume><issue>8</issue><pages><first>i</first><last>x</last><total>10</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Current Awareness</value></json:item><json:item><value>Current Awareness</value></json:item></subject></host><namedEntities><unitex><date><json:string>2009</json:string><json:string>1986</json:string><json:string>1-1-5</json:string></date><geogName><json:string>Sth</json:string><json:string>Lake Ave Nth</json:string></geogName><orgName><json:string>Denmark Hill, London SE</json:string><json:string>Eli Lilly Canada Inc, Res</json:string><json:string>Natural Herbal Farm Inc</json:string><json:string>All India Inst Med Sci, Dept Nephrol, IN</json:string><json:string>Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Div Nephrol</json:string><json:string>Jikei University</json:string><json:string>GlaxoSmithKline Inc</json:string><json:string>Natl Taiwan Univ Hosp, Dept Neurol</json:string><json:string>OXON Epidemiology Ltd</json:string><json:string>Amgen Inc</json:string><json:string>Department Psychiat</json:string><json:string>Lebanon, NH</json:string><json:string>University Pennsylvania School Medicine, Center</json:string><json:string>Denver, Co</json:string><json:string>Sons, Ltd.</json:string><json:string>JBM Ltd</json:string><json:string>Affiliated Hospital, Zhejiang Univ, Coll Med, Dept Gastroenterol, CN</json:string><json:string>US and European</json:string><json:string>Lilly Corp</json:string><json:string>Pfizer Inc</json:string><json:string>Technion - Israel Inst Technol</json:string><json:string>Natl Taiwan Univ Hosp, Dept Internal Med, Div Infect Dis, Infect Dis Sect</json:string><json:string>US/FDA, Off Surveillance</json:string><json:string>Sudbury CO</json:string><json:string>A Belgium Case Series</json:string><json:string>Nat Taiwan Univ, Coll Publ Hlth, Inst Hlth Policy</json:string><json:string>Singapore, Rep Singapore</json:string><json:string>Australia and Northern Europe</json:string><json:string>Beth Israel Deaconess Med Ctr, Baron Edmond Rothschild Chem Dependency Inst</json:string><json:string>Wake Forest University</json:string><json:string>Sons, Ltd</json:string><json:string>US/FDA, Ctr Drug Evaluation</json:string><json:string>Department Clinical</json:string><json:string>Kashiwa Hospital, School Medicine, Department Internal Medicine, Div Gastroenterol</json:string><json:string>Hospital Dr NW, Calgary, Alberta, Canada T</json:string><json:string>Department Med</json:string><json:string>All India Inst Med Sci, Dept Hematol, IN</json:string><json:string>Department Med, Infect Dis Serv</json:string><json:string>American College of Rheumatology Ad Hoc Group on Use of Selective</json:string><json:string>Singapore Gen Hosp, Dept Gastroenterol</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Ann Pharmacother</json:string><json:string>Div Epidemiol</json:string><json:string>Paul Sabatier</json:string><json:string>Div Infect</json:string><json:string>R. Addenbrookes</json:string><json:string>Caroline St</json:string><json:string>M. Med</json:string><json:string>Queen Elizabeth</json:string><json:string>Div Rheumatol</json:string><json:string>N. Showa</json:string><json:string>Van Vliet</json:string><json:string>Div Immunobiol</json:string><json:string>La Pitie-Salpetriere</json:string><json:string>Gen Med</json:string><json:string>L. Telemark</json:string><json:string>Ann Fr</json:string><json:string>Stanislas Torrents</json:string><json:string>Eli Lilly</json:string><json:string>C. Hosp</json:string><json:string>Div Renal</json:string><json:string>P. Boston</json:string><json:string>Div Internal</json:string><json:string>M. Univ</json:string><json:string>L. Address</json:string><json:string>Olav Kyrresgt</json:string><json:string>Huseyin Onat</json:string><json:string>Van Heesweg</json:string><json:string>T. Address</json:string><json:string>Wales Dept</json:string><json:string>Div Nephrol</json:string><json:string>A. Ctr</json:string><json:string>J. Haukeland</json:string><json:string>Camille Desmoulins</json:string><json:string>Molewaterpl</json:string><json:string>Hong Kong</json:string><json:string>A. Dept</json:string><json:string>German Heart</json:string><json:string>Ann Oncol</json:string><json:string>Div Reprod</json:string><json:string>Wayne State</json:string><json:string>Ave Nellie</json:string><json:string>Martin Lago</json:string><json:string>Univ Maryland</json:string><json:string>Indiana Univ</json:string><json:string>Val de Grace</json:string><json:string>S. Mursel</json:string><json:string>P. Radboud</json:string><json:string>C. Nippon</json:string><json:string>U. FoU-Centrum</json:string><json:string>Kent Ridge</json:string><json:string>S. Brigham</json:string><json:string>Leslie Dan</json:string><json:string>Via Vespro</json:string><json:string>Div Pharmacol</json:string><json:string>Ave Nth</json:string><json:string>Div Nefrol</json:string><json:string>Ave Claude</json:string><json:string>Div Cardiol</json:string><json:string>El Venizelou</json:string><json:string>Vasco da Gama</json:string><json:string>Giulio Cesare</json:string><json:string>Princess Margaret</json:string><json:string>R. McGill</json:string><json:string>S. Harvard</json:string><json:string>Shiraz Univ</json:string><json:string>Ann Adams</json:string><json:string>Van Ruysevelt</json:string><json:string>F. Univ</json:string><json:string>Washington Univ</json:string><json:string>W. Univ</json:string><json:string>Largo Agostino</json:string><json:string>Charles Gairdner</json:string><json:string>K. Stadt</json:string><json:string>Div Hematol</json:string><json:string>Alabama Neurol</json:string><json:string>Div Anesthesiol</json:string><json:string>Brady Urol</json:string><json:string>Opin</json:string><json:string>Williams K. Pfizer</json:string><json:string>Ave Finlande</json:string><json:string>Clay St</json:string><json:string>N. Uludag</json:string><json:string>H. Andradas</json:string><json:string>Victoria Hosp</json:string><json:string>Erasmus MC Sophia</json:string><json:string>Jefferson St</json:string><json:string>Van Solinge</json:string><json:string>Rose C. Hop</json:string><json:string>Milano Bicocca</json:string><json:string>Div Pharmacoepidemiol</json:string><json:string>Div Pediat</json:string><json:string>Fed Ceara</json:string><json:string>Santa Sofia</json:string><json:string>Van Dieren</json:string><json:string>Ann Arbor</json:string><json:string>Virginia Commonwealth</json:string><json:string>R. Childrens</json:string><json:string>J. Dana</json:string><json:string>Ave Hippocrate</json:string><json:string>Ann Hematol</json:string><json:string>L. Yale</json:string><json:string>W. Ospedale</json:string><json:string>Max Zeller</json:string><json:string>Div Gastroenterol</json:string><json:string>A. Ben Gurion</json:string><json:string>Via Savonarola</json:string><json:string>El Moutaoui</json:string><json:string>Via Massarenti</json:string><json:string>Via Cadore</json:string><json:string>Div Neurosci</json:string><json:string>O. Kameda</json:string><json:string>F. Hosp</json:string><json:string>P. Univ</json:string><json:string>Sadi Konuk</json:string><json:string>Lee Moffitt</json:string><json:string>Rhabdomyolysis</json:string><json:string>D. Harvard</json:string><json:string>Henry Poincare</json:string><json:string>Gen Psychiatry</json:string><json:string>A. Univ</json:string><json:string>R. Univ</json:string><json:string>Via Eremo</json:string><json:string>Napoleon B. Complexo</json:string><json:string>Kai Suan</json:string><json:string>Shan Sth</json:string><json:string>S. Bakirkoy</json:string><json:string>Alfred Nobel</json:string><json:string>Div Clin</json:string><json:string>Chi Mei</json:string><json:string>Case</json:string><json:string>Chaim Sheba</json:string><json:string>Ann Dermatol</json:string><json:string>Ave Paris</json:string><json:string>Div Neonatol</json:string><json:string>Charif El Idrissi</json:string><json:string>Allen A. Pediat</json:string><json:string>Anderson Canc</json:string><json:string>Div Endocrinol</json:string><json:string>F. Complesso</json:string><json:string>V. Univ</json:string><json:string>P. Hop</json:string><json:string>Tennessee Hlth</json:string><json:string>George Hosp</json:string><json:string>Hayden Ave</json:string><json:string>Clinton Ave</json:string><json:string>Louis Univ</json:string><json:string>Leo Saignat</json:string><json:string>G. Univ</json:string><json:string>U. Krankenhaus</json:string><json:string>London Hosp</json:string><json:string>S. McGill</json:string><json:string>Harry Hines</json:string><json:string>G. Yale</json:string><json:string>Wales Hosp</json:string><json:string>E. Arthritis</json:string><json:string>E. Av</json:string><json:string>Div Emergency</json:string><json:string>I. Univ</json:string><json:string>Taylor St</json:string><json:string>N. McGill</json:string><json:string>J. Norwegian</json:string><json:string>Faris Rd</json:string><json:string>Benjamin Franklin</json:string></persName><placeName><json:string>PY</json:string><json:string>Minneapolis</json:string><json:string>Porto Alegre</json:string><json:string>Shiraz</json:string><json:string>Leiden</json:string><json:string>Lund</json:string><json:string>IL</json:string><json:string>Belfort</json:string><json:string>Stanford</json:string><json:string>Yamaguchi</json:string><json:string>Utrecht</json:string><json:string>San Miguel</json:string><json:string>Fukuoka</json:string><json:string>Calgary</json:string><json:string>Berlin</json:string><json:string>Kyoto</json:string><json:string>Pavia</json:string><json:string>Ankara</json:string><json:string>San Diego</json:string><json:string>Kaohsiung</json:string><json:string>Paris</json:string><json:string>Hindorf</json:string><json:string>Rochester</json:string><json:string>Southampton</json:string><json:string>Switzerland</json:string><json:string>Marburg</json:string><json:string>Palermo</json:string><json:string>Colombia</json:string><json:string>Columbia</json:string><json:string>Alicante</json:string><json:string>Greece</json:string><json:string>Perugia</json:string><json:string>San Antonio</json:string><json:string>Bordeaux</json:string><json:string>Nancy</json:string><json:string>Munich</json:string><json:string>Innsbruck</json:string><json:string>Ste Catherine</json:string><json:string>St Luc</json:string><json:string>St James</json:string><json:string>Edmonton</json:string><json:string>NY</json:string><json:string>Australia</json:string><json:string>San Luigi</json:string><json:string>Mexico</json:string><json:string>Bursa</json:string><json:string>Casablanca</json:string><json:string>SY</json:string><json:string>Korea</json:string><json:string>New Delhi</json:string><json:string>Seoul</json:string><json:string>Columbus</json:string><json:string>Brazil</json:string><json:string>Beijing</json:string><json:string>Valencia</json:string><json:string>UK</json:string><json:string>Mendoza</json:string><json:string>St Stephens</json:string><json:string>Norway</json:string><json:string>Tainan</json:string><json:string>Austria</json:string><json:string>Pittsburgh</json:string><json:string>Pisa</json:string><json:string>Vitoria</json:string><json:string>Washington</json:string><json:string>Banja Luka</json:string><json:string>Bangor</json:string><json:string>Lecce</json:string><json:string>Turin</json:string><json:string>Turkey</json:string><json:string>Oklahoma City</json:string><json:string>Sendai</json:string><json:string>Richmond</json:string><json:string>Newark</json:string><json:string>Eppendorf</json:string><json:string>Matsushima</json:string><json:string>Taiwan</json:string><json:string>Edinburgh</json:string><json:string>Canada</json:string><json:string>Genoa</json:string><json:string>Guildford</json:string><json:string>DC</json:string><json:string>Costa Rica</json:string><json:string>Chongqing</json:string><json:string>Oslo</json:string><json:string>Santiago de Compostela</json:string><json:string>Seville</json:string><json:string>Grosshansdorf</json:string><json:string>Oakland</json:string><json:string>Houston</json:string><json:string>Morocco</json:string><json:string>Hangzhou</json:string><json:string>Helsinki</json:string><json:string>Cardiff</json:string><json:string>Hamburg</json:string><json:string>Immunogenicity</json:string><json:string>NC</json:string><json:string>Bremen</json:string><json:string>Skien</json:string><json:string>SC</json:string><json:string>Nottingham</json:string><json:string>San Jose</json:string><json:string>Trondheim</json:string><json:string>Madrid</json:string><json:string>Okayama</json:string><json:string>Monza</json:string><json:string>Mons</json:string><json:string>Ueshima</json:string><json:string>Turku</json:string><json:string>Terrassa</json:string><json:string>Seattle</json:string><json:string>Bologna</json:string><json:string>Haifa</json:string><json:string>Perth</json:string><json:string>China</json:string><json:string>Nijmegen</json:string><json:string>Vancouver</json:string><json:string>Toronto</json:string><json:string>Europe</json:string><json:string>Atlanta</json:string><json:string>Nantes</json:string><json:string>Hebron</json:string><json:string>Milan</json:string><json:string>Los Angeles</json:string><json:string>Athens</json:string><json:string>Japan</json:string><json:string>Wales</json:string><json:string>Baltimore</json:string><json:string>Leeds</json:string><json:string>Kawasaki</json:string><json:string>Vienna</json:string><json:string>Liverpool</json:string><json:string>Barcelona</json:string><json:string>Bergen</json:string><json:string>Basel</json:string><json:string>San Francisco</json:string><json:string>Kolkata</json:string><json:string>Fortaleza</json:string><json:string>Glasgow</json:string><json:string>Denmark</json:string><json:string>Chiba</json:string><json:string>Rome</json:string><json:string>Rotterdam</json:string><json:string>Chicago</json:string><json:string>Patras</json:string><json:string>Coventry</json:string><json:string>ST. Drexel</json:string><json:string>Israel</json:string><json:string>Chichester</json:string><json:string>York</json:string><json:string>Ingolstadt</json:string><json:string>Ottawa</json:string><json:string>St Vincent</json:string><json:string>Lausanne</json:string><json:string>MI</json:string><json:string>Ioannina</json:string><json:string>Leuven</json:string><json:string>Bosnia and Herzegovina</json:string><json:string>St Richards</json:string><json:string>France</json:string><json:string>Quebec</json:string><json:string>WA</json:string><json:string>Burgos</json:string><json:string>Greenville</json:string><json:string>Salem</json:string><json:string>Marseille</json:string><json:string>Hepatotoxicity</json:string><json:string>Tampa</json:string><json:string>Cambridge</json:string><json:string>Indianapolis</json:string><json:string>Italy</json:string><json:string>Istanbul</json:string><json:string>Detroit</json:string><json:string>Sweden</json:string><json:string>Lille</json:string><json:string>England</json:string><json:string>Worcester</json:string><json:string>Warwickshire</json:string><json:string>Catania</json:string><json:string>Mainz</json:string><json:string>Iran</json:string><json:string>Goldberg</json:string><json:string>Neurotoxicity</json:string><json:string>Salzburg</json:string><json:string>Wuhan</json:string><json:string>Lincoln</json:string><json:string>Belgium</json:string><json:string>Netherlands</json:string><json:string>St Olavs</json:string><json:string>Thessaloniki</json:string><json:string>Tucson</json:string><json:string>Zwolle</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Sica et al</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-Z4H8CGGW-Z</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Pharmacology (medical)</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Epidemiology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/pds.1651</json:string></doi><id>D9DDB40CD540E03ED72C36319DCB2DB3F7123960</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-Z4H8CGGW-Z/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-Z4H8CGGW-Z/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-Z4H8CGGW-Z/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title><title level="a" type="short" xml:lang="en">Current Awareness</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><availability><licence>Copyright © 2009 John Wiley & Sons, Ltd.</licence></availability><date type="published" when="2009-08"></date></publicationStmt><notesStmt><note type="content-type" subtype="other" source="bibliography" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="other"><analytic><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title><title level="a" type="short" xml:lang="en">Current Awareness</title><idno type="istex">D9DDB40CD540E03ED72C36319DCB2DB3F7123960</idno><idno type="ark">ark:/67375/WNG-Z4H8CGGW-Z</idno><idno type="DOI">10.1002/pds.1651</idno><idno type="unit">PDS1651</idno><idno type="toTypesetVersion">file:PDS.PDS1651.pdf</idno></analytic><monogr><title level="j" type="main">Pharmacoepidemiology and Drug Safety</title><title level="j" type="alt">PHARMACOEPIDEMIOLOGY AND DRUG SAFETY</title><idno type="pISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><idno type="book-DOI">10.1002/(ISSN)1099-1557</idno><idno type="book-part-DOI">10.1002/pds.v18:8</idno><idno type="product">PDS</idno><imprint><biblScope unit="vol">18</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="i">i</biblScope><biblScope unit="page" to="x">x</biblScope><biblScope unit="page-count">10</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2009-08"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. </p></abstract><textClass><keywords rend="articleCategory"><term>Current Awareness</term></keywords><keywords rend="tocHeading1"><term>Current Awareness</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-Z4H8CGGW-Z/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Ltd.</publisherName><publisherLoc>Chichester, UK</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1099-1557</doi><issn type="print">1053-8569</issn><issn type="electronic">1099-1557</issn><idGroup><id type="product" value="PDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="PHARMACOEPIDEMIOLOGY AND DRUG SAFETY">Pharmacoepidemiology and Drug Safety</title><title type="short">Pharmacoepidem. Drug Safe.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/pds.v18:8</doi><numberingGroup><numbering type="journalVolume" number="18">18</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2009-08">August 2009</coverDate></publicationMeta><publicationMeta level="unit" type="bibliography" position="999" status="forIssue"><doi origin="wiley" registered="yes">10.1002/pds.1651</doi><idGroup><id type="unit" value="PDS1651"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="articleCategory">Current Awareness</title><title type="tocHeading1">Current Awareness</title></titleGroup><copyright ownership="publisher">Copyright © 2009 John Wiley & Sons, Ltd.</copyright><eventGroup><event type="firstOnline" date="2009-07-24"></event><event type="publishedOnlineFinalForm" date="2009-07-24"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.12 mode:FullText source:FullText result:FullText" date="2010-07-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-06"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event></eventGroup><numberingGroup><numbering type="pageFirst">i</numbering><numbering type="pageLast">x</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:PDS.PDS1651.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="315"></count></countGroup><titleGroup><title type="main" xml:lang="en">Current awareness: Pharmacoepidemiology and drug safety</title><title type="short" xml:lang="en">Current Awareness</title></titleGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. </p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Current awareness: Pharmacoepidemiology and drug safety</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Current Awareness</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Current awareness: Pharmacoepidemiology and drug safety</title></titleInfo><typeOfResource>text</typeOfResource><genre type="other" displayLabel="bibliography" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</genre><originInfo><publisher>John Wiley & Sons, Ltd.</publisher><place><placeTerm type="text">Chichester, UK</placeTerm></place><dateIssued encoding="w3cdtf">2009-08</dateIssued><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">0</extent><extent unit="references">315</extent></physicalDescription><abstract lang="en">In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</abstract><relatedItem type="host"><titleInfo><title>Pharmacoepidemiology and Drug Safety</title></titleInfo><titleInfo type="abbreviated"><title>Pharmacoepidem. Drug Safe.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Current Awareness</topic><topic>Current Awareness</topic></subject><identifier type="ISSN">1053-8569</identifier><identifier type="eISSN">1099-1557</identifier><identifier type="DOI">10.1002/(ISSN)1099-1557</identifier><identifier type="PublisherID">PDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>i</start><end>x</end><total>10</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>1. Reviews</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Strategies for minimizing corticosteroid toxicity: A review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aulakh R, Singh S. Strategies for minimizing corticosteroid toxicity: A review. Indian J Pediatr (2008); 75: 1067.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>1067</start></extent></part><relatedItem type="host"><titleInfo><title>Indian J Pediatr</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>1067</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Agalsidase α for the treatment of Fabry disease: New data on clinical efficacy and safety</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Beck M. Agalsidase α for the treatment of Fabry disease: New data on clinical efficacy and safety. Expert Opin Biol Ther (2009); 9: 255.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>255</start></extent></part><relatedItem type="host"><titleInfo><title>Expert Opin Biol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>255</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Aspirin in cardiology ‐ Benefits and risks</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bjorklund L, Wallander MA, Johansson S, Lesen E. Aspirin in cardiology ‐ Benefits and risks. Int J Clin Pract (2009); 63: 468.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>468</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Clin Pract</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>468</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Gadolinium‐associated nephrogenic systemic fibrosis: The need for nephrologists' awareness</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P. Gadolinium‐associated nephrogenic systemic fibrosis: The need for nephrologists' awareness. J Nephrol (2008); 21: 324.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>324</start></extent></part><relatedItem type="host"><titleInfo><title>J Nephrol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>324</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Determination of human teratogenicity by the astute clinician method: Review of illustrative agents and a proposal of guidelines</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carey JC, Martinez L, Balken E, Leen‐Mitchell M, Robertson J. Determination of human teratogenicity by the astute clinician method: Review of illustrative agents and a proposal of guidelines. Birth Defects Res A Clin Mol Teratol (2009); 85: 63.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>63</start></extent></part><relatedItem type="host"><titleInfo><title>Birth Defects Res A Clin Mol Teratol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>63</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Risk of hand‐foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non‐renal cell carcinoma: A meta analysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chu D, Lacouture ME, Weiner E, Wu SH. Risk of hand‐foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non‐renal cell carcinoma: A meta analysis. Clin Genitourin Cancer (2009); 7: 11.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>11</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Genitourin Cancer</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>11</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: Focus on rituximab</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fleischmann RA. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: Focus on rituximab. Semin Arthritis Rheum (2009); 38: 265.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>265</start></extent></part><relatedItem type="host"><titleInfo><title>Semin Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>265</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Anticoagulants and pregnancy: When are they safe?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gibson PS, Powrie R. Anticoagulants and pregnancy: When are they safe?. Cleve Clin J Med (2009); 76: 113.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>113</start></extent></part><relatedItem type="host"><titleInfo><title>Cleve Clin J Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>113</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Review on use of German health insurance medication claims data for epidemiological research</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hoffmann F. Review on use of German health insurance medication claims data for epidemiological research. Pharmacoepidemiol Drug Saf (2009); 18: 349.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>349</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>349</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Drug‐induced thrombocytopenia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kenney B, Stack G. Drug‐induced thrombocytopenia. Arch Pathol Lab Med (2009); 133: 309.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>133</number></detail><extent unit="pages"><start>309</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Pathol Lab Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>133</number></detail><extent unit="pages"><start>309</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Arterial hypertension induced by erythropoietin and erythropoiesis‐stimulating agents (ESA)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis‐stimulating agents (ESA). Clin J Am Soc Nephrol (2009); 4: 470.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>470</start></extent></part><relatedItem type="host"><titleInfo><title>Clin J Am Soc Nephrol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>470</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Vision disorders and phosphodiesterase type 5 inhibitors. A review of the evidence to date</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors. A review of the evidence to date. Drug Saf (2009); 32: 1.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Determinants of under‐reporting of adverse drug reactions. A systematic review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lopez‐Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under‐reporting of adverse drug reactions. A systematic review. Drug Saf (2009); 32: 19.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>19</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>19</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Review and expert recommendations</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martin M, Esteva FJ, Alba E, Khandheria B, Perez‐Isla L, Garcia‐Saenz JA, Marquez A, Sengupta P, Zamorano J. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Review and expert recommendations. Oncologist (2009); 14: 1.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>Oncologist</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Antiepileptic drug‐induced cognitive adverse effects potential mechanisms and contributing factors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mula M, Trimble MR. Antiepileptic drug‐induced cognitive adverse effects potential mechanisms and contributing factors. CNS Drugs (2009); 23: 121.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>121</start></extent></part><relatedItem type="host"><titleInfo><title>CNS Drugs</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>121</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Safety assessment and dose selection for first‐in‐human clinical trials with immunomodulatory monoclonal antibodies</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Muller PY, Brennan FR. Safety assessment and dose selection for first‐in‐human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther (2009); 85: 247.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>247</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>247</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Calcineurin inhibitor nephrotoxicity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol (2009); 4: 481.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>481</start></extent></part><relatedItem type="host"><titleInfo><title>Clin J Am Soc Nephrol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>481</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d‐amphetamine, for the treatment of attention‐deficit/hyperactivity disorder in children and adults</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d‐amphetamine, for the treatment of attention‐deficit/hyperactivity disorder in children and adults. Clin Ther (2009); 31: 142.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>142</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>142</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Dental surgery for patients on anticoagulant therapy with warfarin: A systematic review and meta‐analysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nematullah A, Alabousi A, Blanas N, Douketis JD, Sutherland SE. Dental surgery for patients on anticoagulant therapy with warfarin: A systematic review and meta‐analysis. J Can Dent Assoc (2009); 75: 41.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>41</start></extent></part><relatedItem type="host"><titleInfo><title>J Can Dent Assoc</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>41</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Current status of gadolinium toxicity in patients with kidney disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol (2009); 4: 461.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>461</start></extent></part><relatedItem type="host"><titleInfo><title>Clin J Am Soc Nephrol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>461</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Effect of folic or folinic acid supplementation on methotrexate‐associated safety and efficacy in inflammatory disease: A sytematic review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate‐associated safety and efficacy in inflammatory disease: A sytematic review. Br J Dermatol (2009); 160: 622.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>160</number></detail><extent unit="pages"><start>622</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>160</number></detail><extent unit="pages"><start>622</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>The efficacy and safety of cilomilast in COPD</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rennard S, Knobil K, Rabe KF, Morris A, Schachter N, Locantore N, Canonica WG, Zhu YJ, Barnhart F. The efficacy and safety of cilomilast in COPD. Drugs (2008); 68: 3.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>3</start></extent></part><relatedItem type="host"><titleInfo><title>Drugs</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>3</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Dermatological symptoms associated with the multikinase inhibitor sorafenib</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatological symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol (2009); 60: 299.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>299</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>299</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>EUS contrast agents: What is available, how do they work, and are they effective?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sanchez MVA, Varadarajulu S, Napoleon B. EUS contrast agents: What is available, how do they work, and are they effective?. Gastrointest Endosc (2009); 69: S71.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>S71</start></extent></part><relatedItem type="host"><titleInfo><title>Gastrointest Endosc</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>S71</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Adverse drug reactions and the skin—from trivial to fire signal (German, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Scherer K, Bircher A. Adverse drug reactions and the skin—from trivial to fire signal (German, English Abstract). Internist (Berl) (2009); 50: 171.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>171</start></extent></part><relatedItem type="host"><titleInfo><title>Internist (Berl)</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>171</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Drug‐drug interactions involving new antiretroviral drugs and drug classes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Soodalter J, Sousa M, Boffito M. Drug‐drug interactions involving new antiretroviral drugs and drug classes. Curr Opin Infect Dis (2009); 22: 18.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>18</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Infect Dis</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>18</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Immune‐mediated adverse drug reactions</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Uetrecht J. Immune‐mediated adverse drug reactions. Chem Res Toxicol (2009); 22: 24.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>24</start></extent></part><relatedItem type="host"><titleInfo><title>Chem Res Toxicol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>24</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>Pharmacovigilance in traditional Chinese medicine safety surveillance</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wang H, Ye X, Gao Q, Wu C, Qian Y, Luo B, Sun Y, He J. Pharmacovigilance in traditional Chinese medicine safety surveillance. Pharmacoepidemiol Drug Saf (2009); 18: 357.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>357</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>357</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>Pregnancy exposure registries: Academic opportunities and industry responsibility</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wyszynski DF. Pregnancy exposure registries: Academic opportunities and industry responsibility. Birth Defects Res A Clin Mol Teratol (2009); 85: 93.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>93</start></extent></part><relatedItem type="host"><titleInfo><title>Birth Defects Res A Clin Mol Teratol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>93</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>2. General</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first‐in‐human trials of high‐risk biologics</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Agoram BM. Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first‐in‐human trials of high‐risk biologics. Br J Clin Pharmacol (2009); 67: 153.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>153</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>153</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>Use of disease risk scores in pharmacoepidemiologic studies</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res (2009); 18: 67.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>67</start></extent></part><relatedItem type="host"><titleInfo><title>Stat Methods Med Res</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>67</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>Evolution of drug consumption in a sample of French workers since 1986: The ‘Drugs and Works’ Study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Boeuf‐Cazou O, Lapeyre‐Mestre M, Niezborala M, Montastruc JL. Evolution of drug consumption in a sample of French workers since 1986: The ‘Drugs and Works’ Study. Pharmacoepidemiol Drug Saf (2009); 18: 335.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>335</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>335</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>Prescribing discrepancies likely to cause adverse drug events after patient transfer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Boockvar KS, Liu S, Goldstein N, Nebeker J, Siu A, Fried T. Prescribing discrepancies likely to cause adverse drug events after patient transfer. Qual Saf Health Care (2009); 18: 32.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>32</start></extent></part><relatedItem type="host"><titleInfo><title>Qual Saf Health Care</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>32</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>Characteristics of outpatient prescriptions for frail Taiwanese elders with long‐term care needs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chan DC, Hao YT, Wu SC. Characteristics of outpatient prescriptions for frail Taiwanese elders with long‐term care needs. Pharmacoepidemiol Drug Saf (2009); 18: 327.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>327</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>327</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>Data‐driven methods to discover molecular determinants of serious adverse drug events</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chiang AP, Butte AJ. Data‐driven methods to discover molecular determinants of serious adverse drug events. Clin Pharmacol Ther (2009); 85: 259.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>259</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>259</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>The case‐crossover study design in pharmacoepidemiology</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Delaney JA, Suissa S. The case‐crossover study design in pharmacoepidemiology. Stat Methods Med Res (2009); 18: 53.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>53</start></extent></part><relatedItem type="host"><titleInfo><title>Stat Methods Med Res</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>53</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>Paediatric homoeopathy in Germany: Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Du Y, Knopf H. Paediatric homoeopathy in Germany: Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Pharmacoepidemiol Drug Saf (2009); 18: 370.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>370</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>370</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>Risk of cataract among idiopathic thrombocytopenic purpura patients in the UK general practice research database</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Feudjo‐Tepie MA, Hall SA, Logie J, Robinson NJ. Risk of cataract among idiopathic thrombocytopenic purpura patients in the UK general practice research database. Pharmacoepidemiol Drug Saf (2009); 18: 380.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>380</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>380</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>Drug‐Induced Liver Injury Network (DILIN) prospective study rationale, design and conduct</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J. Drug‐Induced Liver Injury Network (DILIN) prospective study rationale, design and conduct. Drug Saf (2009); 32: 55.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>55</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>55</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Efficient sampling approaches to address confounding in database studies</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hanley JA, Dendukuri N. Efficient sampling approaches to address confounding in database studies. Stat Methods Med Res (2009); 18: 81.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>81</start></extent></part><relatedItem type="host"><titleInfo><title>Stat Methods Med Res</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>81</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>Using secondary data sources for pharmacoepidemiology and outcomes research</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Harpe SE. Using secondary data sources for pharmacoepidemiology and outcomes research. Pharmacotherapy (2009); 29: 138.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>138</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>138</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>Observation plans in longitudinal studies with time‐varying treatments</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hernan MA, McAdams M, McGrath N, Lanoy E, Costagliola D. Observation plans in longitudinal studies with time‐varying treatments. Stat Methods Med Res (2009); 18: 27.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>27</start></extent></part><relatedItem type="host"><titleInfo><title>Stat Methods Med Res</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>27</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>Drug safety and the role of clinical pharmacology in the safe use of therapeutics (Editorial comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Honig PK. Drug safety and the role of clinical pharmacology in the safe use of therapeutics (Editorial comment). Clin Pharmacol Ther (2009); 85: 225.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>225</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>225</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>Prevalence of adverse drug combinations in a large post‐mortem toxicology database</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Launiainen T, Vuori E, Ojanpera I. Prevalence of adverse drug combinations in a large post‐mortem toxicology database. Int J Legal Med (2009); 123: 109.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>109</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Legal Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>109</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>Polypharmacy, inappropriate prescribing and adverse drug reactions in Austria (Editorial comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Muller M. Polypharmacy, inappropriate prescribing and adverse drug reactions in Austria (Editorial comment). Wien Klin Wochenschr (2008); 120: 713.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>120</number></detail><extent unit="pages"><start>713</start></extent></part><relatedItem type="host"><titleInfo><title>Wien Klin Wochenschr</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>120</number></detail><extent unit="pages"><start>713</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>Insufficient information in drug‐related hospital morbidity study (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Newman RG. Insufficient information in drug‐related hospital morbidity study (Letter). Arch Gen Psychiatry (2009); 66: 331.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>331</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Gen Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>331</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>Insufficient information in drug‐related hospital morbidity study (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ngo HTT, Tait RJ, Hulse GK. Insufficient information in drug‐related hospital morbidity study (Reply). Arch Gen Psychiatry (2009); 66: 331.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>331</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Gen Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>331</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit50"><titleInfo><title>Comparison of health insurance claims and patient interviews in assessing drug use: Data from the Three‐City (3C) Study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Noize P, Bazin F, Dufouil C, Lechevallier‐Michel N, Ancelin ML, Dartigues JF, Tzourio C, Moore N, Fourrier‐Reglat A. Comparison of health insurance claims and patient interviews in assessing drug use: Data from the Three‐City (3C) Study. Pharmacoepidemiol Drug Saf (2009); 18: 310.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>310</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>310</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit51"><titleInfo><title>An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: A time series analysis in Spain</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pedros C, Vallano A, Cereza G, Mendoza‐Aran G, Agusti A, Aguilera C, Danes I, Vidal X, Arnau JM. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: A time series analysis in Spain. Drug Saf (2009); 32: 77.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>77</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>77</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit52"><titleInfo><title>Clarification to the www.qtdrugs.org updated lists (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Romero K, Woosley RL. Clarification to the www.qtdrugs.org updated lists (Letter). Pharmacoepidemiol Drug Saf (2009); 18: 423.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>423</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>423</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit53"><titleInfo><title>Polypharmacy and inappropriate prescribing in elderly internal‐medicine patients in Austria</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schuler J, Duckelmann C, Beindl W, Prinz E, Michalski T, Pichler M. Polypharmacy and inappropriate prescribing in elderly internal‐medicine patients in Austria. Wien Klin Wochenschr (2008); 120: 733.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>120</number></detail><extent unit="pages"><start>733</start></extent></part><relatedItem type="host"><titleInfo><title>Wien Klin Wochenschr</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>120</number></detail><extent unit="pages"><start>733</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit54"><titleInfo><title>Perspectives on early communication of drug risks to the public</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Seligman PJ, Osborne SF. Perspectives on early communication of drug risks to the public. Clin Pharmacol Ther (2009); 85: 335.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>335</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>335</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit55"><titleInfo><title>Monitoring for hepatotoxicity: What is the predictive value of liver /function/ tests?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Senior JR. Monitoring for hepatotoxicity: What is the predictive value of liver /function/ tests?. Clin Pharmacol Ther (2009); 85: 331.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>331</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>331</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit56"><titleInfo><title>Statistical methods in pharmacoepidemiology: Advances and challenges (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Suissa S. Statistical methods in pharmacoepidemiology: Advances and challenges (Editorial). Stat Methods Med Res (2009); 18: 3.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>3</start></extent></part><relatedItem type="host"><titleInfo><title>Stat Methods Med Res</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>3</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit57"><titleInfo><title>Drug‐induced thrombocytopenia: An updated systematic review, 2008 (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Swisher KK, Li XN, Vesely SK, George JN. Drug‐induced thrombocytopenia: An updated systematic review, 2008 (Letter). Drug Saf (2009); 32: 85.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>85</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>85</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit58"><titleInfo><title>Platelet measurements versus discharge diagnoses for identification of patients with potential drug‐induced thrombocytopenia: A cross‐sectional study in the Netherlands</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ten Berg MJ, Van Solinge WW, Van den Bemt PMLA, Huisman A, Schobben AFAM, Egberts TCG. Platelet measurements versus discharge diagnoses for identification of patients with potential drug‐induced thrombocytopenia: A cross‐sectional study in the Netherlands. Drug Saf (2009); 32: 69.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>69</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>69</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit59"><titleInfo><title>Measuring benefit and balancing risk: Strategies for the benefit‐risk assessment of new medicines in a risk‐averse environment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Walker S, McAuslane N, Liberti L, Salek S. Measuring benefit and balancing risk: Strategies for the benefit‐risk assessment of new medicines in a risk‐averse environment. Clin Pharmacol Ther (2009); 85: 241.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>241</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>241</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit60"><titleInfo><title>The methodology of self‐controlled case series studies</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Whitaker HJ, Hocine MN, Farrington CP. The methodology of self‐controlled case series studies. Stat Methods Med Res (2009); 18: 7.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>7</start></extent></part><relatedItem type="host"><titleInfo><title>Stat Methods Med Res</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>7</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit61"><titleInfo><title>3. Anti‐infective Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit62"><titleInfo><title>Gene variants of IL13, IL4, and IL4RA are predictors of β‐lactam allergy (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Apter AJ, Schelleman H, Rebbeck T. Gene variants of IL13, IL4, and IL4RA are predictors of β‐lactam allergy (Reply). J Allergy Clin Immunol (2009); 123: 509.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>509</start></extent></part><relatedItem type="host"><titleInfo><title>J Allergy Clin Immunol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>509</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit63"><titleInfo><title>Safety and tolerability of ertapenem versus ceftriaxone in a double‐blind study performed in children with complicated urinary tract infection, community‐acquired pneumonia or skin and soft‐tissue infection</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Arguedas A, Cespedes J, Botet FA, Blumer J, Yogev R, Gesser R, Wang J, West J, Snyder T, Wimmer W. Safety and tolerability of ertapenem versus ceftriaxone in a double‐blind study performed in children with complicated urinary tract infection, community‐acquired pneumonia or skin and soft‐tissue infection. Int J Antimicrob Agents (2009); 33: 163.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>163</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Antimicrob Agents</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>163</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit64"><titleInfo><title>Mansonella perstans: Safety and efficacy of ivermectin alone, albendazole alone and the two drugs in combination</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Asio SM, Simonsen PE, Onapa AW. Mansonella perstans: Safety and efficacy of ivermectin alone, albendazole alone and the two drugs in combination. Ann Trop Med Parasitol (2009); 103: 31.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>31</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Trop Med Parasitol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>31</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit65"><titleInfo><title>Sudden cardiac arrest in a patient taking chloroquine (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aslanger E. Sudden cardiac arrest in a patient taking chloroquine (Letter). Resuscitation (2009); 80: 285.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>285</start></extent></part><relatedItem type="host"><titleInfo><title>Resuscitation</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>285</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit66"><titleInfo><title>Trimethoprim sulfamethoxazole‐induced Sweet syndrome (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Azfar RS, Cohn J, Schaffer A, Kim EJ. Trimethoprim sulfamethoxazole‐induced Sweet syndrome (Letter). Arch Dermatol (2009); 145: 215.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>145</number></detail><extent unit="pages"><start>215</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>145</number></detail><extent unit="pages"><start>215</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit67"><titleInfo><title>A rapid method for detection of five known mutations associated with aminoglycoside‐induced deafness</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bardien S, Human H, Harris T, Hefke G, Veikondis R, Schaaf HS, Van der Merwe L, Greinwald JH, Fagan J, De Jong G. A rapid method for detection of five known mutations associated with aminoglycoside‐induced deafness. BMC Med Genet (2009); 10: 2.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>2</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Med Genet</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>2</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit68"><titleInfo><title>When an antibiotic becomes toxic (Letter) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Batjom E, Franck L, Dubost C, Rouquette‐Vincenti I. When an antibiotic becomes toxic (Letter) (French). Ann Fr Anesth Reanim (2009); 28: 105.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>105</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Fr Anesth Reanim</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>105</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit69"><titleInfo><title>Acute kidney injury, hepatitis, and CPK elevation associated with nitrofurantoin therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Beigel R, Perets R, Mouallem M. Acute kidney injury, hepatitis, and CPK elevation associated with nitrofurantoin therapy. Am J Med Sci (2009); 337: 132.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>337</number></detail><extent unit="pages"><start>132</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Med Sci</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>337</number></detail><extent unit="pages"><start>132</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit70"><titleInfo><title>Auditory nerve neuropathy in a neonate after linezolid treatment (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brennan K, Jones BL, Jackson L. Auditory nerve neuropathy in a neonate after linezolid treatment (Letter). Pediatr Infect Dis J (2009); 28: 169.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>169</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Infect Dis J</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>169</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit71"><titleInfo><title>Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carmona‐Fonseca J, Alvarez G, Maestre A. Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment. Am J Trop Med Hyg (2009); 80: 188.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>188</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Trop Med Hyg</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>188</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit72"><titleInfo><title>The risks of long‐term nitrofurantoin prophylaxis in patients with recurrent urinary tract infection: A recent medico‐legal case</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cetti RJ, Venn S, Woodhouse CRJ. The risks of long‐term nitrofurantoin prophylaxis in patients with recurrent urinary tract infection: A recent medico‐legal case. BJU Int (2009); 103: 567.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>567</start></extent></part><relatedItem type="host"><titleInfo><title>BJU Int</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>567</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit73"><titleInfo><title>Sweet syndrome induced by chloroquine (Letter) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">El Moutaoui L, Zouhair K, Benchikhi H. Sweet syndrome induced by chloroquine (Letter) (French). Ann Dermatol Venereol (2009); 136: 56.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>136</number></detail><extent unit="pages"><start>56</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Dermatol Venereol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>136</number></detail><extent unit="pages"><start>56</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit74"><titleInfo><title>Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: A meta‐analysis of randomized trials</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Falagas ME, Karageorgopoulos DE, Grammatikos AP, Matthaiou DK. Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: A meta‐analysis of randomized trials. Br J Clin Pharmacol (2009); 67: 161.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>161</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>161</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit75"><titleInfo><title>Immunogenicity and safety of live attenuated hepatitis A vaccine: A multicentric study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Faridi MMA, Shah N, Ghosh TK, Sankaranarayanan VS, Arankalle V, Aggarwal A, Sathiyasekaran M, Bhattacharya N, Vasanthi T, Chatterjee S, Choudhury J, Mitra M. Immunogenicity and safety of live attenuated hepatitis A vaccine: A multicentric study. Indian Pediatr (2009); 46: 29.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>29</start></extent></part><relatedItem type="host"><titleInfo><title>Indian Pediatr</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>29</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit76"><titleInfo><title>Vancomycin ototoxicity: A reevaluation in an era of increasing doses</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: A reevaluation in an era of increasing doses. Antimicrob Agents Chemother (2009); 53: 483.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>483</start></extent></part><relatedItem type="host"><titleInfo><title>Antimicrob Agents Chemother</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>483</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit77"><titleInfo><title>Renal failure is a risk factor for cefepime‐induced encephalopathy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Garces EO, De Azambuja MFA, Da Silva D, Bragatti JA, Jacoby T, Thome FS. Renal failure is a risk factor for cefepime‐induced encephalopathy. J Nephrol (2008); 21: 526.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>526</start></extent></part><relatedItem type="host"><titleInfo><title>J Nephrol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>526</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit78"><titleInfo><title>Gene variants of IL13, IL4, and IL4RA are predictors of β‐lactam allergy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gueant JL, Gueant‐Rodriguez RM, Cornejo‐Garcia JA, Viola M, Blanca M, Romano A. Gene variants of IL13, IL4, and IL4RA are predictors of β‐lactam allergy (Letter). J Allergy Clin Immunol (2009); 123: 509.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>509</start></extent></part><relatedItem type="host"><titleInfo><title>J Allergy Clin Immunol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>509</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit79"><titleInfo><title>Efficacy and safety of ritonavir‐boosted and unboosted atazanavir among antiretroviral‐naive patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Horberg M, Klein D, Hurley L, Silverberg M, Towner W, Antoniskis D, Kovach D, Mogyoros M, Blake W, Dobrinich R, Dodge W. Efficacy and safety of ritonavir‐boosted and unboosted atazanavir among antiretroviral‐naive patients. HIV Clin Trials (2008); 9: 367.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>367</start></extent></part><relatedItem type="host"><titleInfo><title>HIV Clin Trials</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>367</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit80"><titleInfo><title>Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX‐355), and anti‐CD4 monoclonal antibody, in human immunodeficiency virus type 1‐infected adults</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX‐355), and anti‐CD4 monoclonal antibody, in human immunodeficiency virus type 1‐infected adults. Antimicrob Agents Chemother (2009); 53: 450.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>450</start></extent></part><relatedItem type="host"><titleInfo><title>Antimicrob Agents Chemother</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>450</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit81"><titleInfo><title>Hypotension due to the drug interaction of voriconazole with eplerenone and nifedipine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kato J, Mori T, Nakamura Y, Sakurai M, Aisa Y, Ikeda Y, Okamoto S. Hypotension due to the drug interaction of voriconazole with eplerenone and nifedipine. Eur J Clin Pharmacol (2009); 65: 323.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>323</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>323</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit82"><titleInfo><title>Gatifloxacin‐induced severe hyperglycaemia and ketoacidosis in a non‐diabetic renal transplant recipient</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Khaira A, Gupta A, Tandon N, Agarwal SK. Gatifloxacin‐induced severe hyperglycaemia and ketoacidosis in a non‐diabetic renal transplant recipient. Clin Exp Nephrol (2009); 13: 89.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>89</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Nephrol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>89</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit83"><titleInfo><title>Intracranial hypertension and levofloxacin: A case report</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lardizabal DV. Intracranial hypertension and levofloxacin: A case report. Headache (2009); 49: 300.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>300</start></extent></part><relatedItem type="host"><titleInfo><title>Headache</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>300</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit84"><titleInfo><title>Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liang SH, Sheng WH, Huang YT, Wu FLL, Chang SC. Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population. Chemotherapy (2009); 55: 91.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>91</start></extent></part><relatedItem type="host"><titleInfo><title>Chemotherapy</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>91</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit85"><titleInfo><title>Peripheral neuropathy in an adolescent treated with linezolid</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Linam WM, Wesselkamper K, Gerber MA. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr Infect Dis J (2009); 28: 149.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>149</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Infect Dis J</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>149</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit86"><titleInfo><title>Fine‐tuning the safety and immunogenicity of Listeria monocytogenes‐based neonatal vaccine platforms</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Loeffler DIM, Smolen K, Aplin L, Cai B, Kollmann TR. Fine‐tuning the safety and immunogenicity of Listeria monocytogenes‐based neonatal vaccine platforms. Vaccine (2009); 27: 919.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>919</start></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>919</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit87"><titleInfo><title>Depressive symptoms and exposure to efavirenz in West African HIV‐infected adults (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marcellin F, Moh R, Carrieri MP, Danel C, Protopopescu C, Gabillard D, Spire B, Anglaret X. Depressive symptoms and exposure to efavirenz in West African HIV‐infected adults (Letter). HIV Clin Trials (2008); 9: 445.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>445</start></extent></part><relatedItem type="host"><titleInfo><title>HIV Clin Trials</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>445</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit88"><titleInfo><title>Cefoperazone induced gastro‐intestinal haemorrhage. A case report</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ozen IO, Moralioglu S, Karabulut R, Bagbanci B, Turkyilmaz Z, Demirogullari B, Sonmez K, Basaklar AC, Kale N. Cefoperazone induced gastro‐intestinal haemorrhage. A case report. Acta Chir Belg (2008); 108: 777.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>777</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Chir Belg</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>777</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit89"><titleInfo><title>The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pertel PE, Eisenstein BI, Link AS, Donfrid B, Biermann EJA, Bernardo P, Martone WJ. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract (2009); 63: 368.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>368</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Clin Pract</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>368</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit90"><titleInfo><title>A paediatric case of acute liver failure associated with efavirenz‐based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Turkova A, Ball C, Gilmour‐White S, Rela M, Mieli‐Vergani G. A paediatric case of acute liver failure associated with efavirenz‐based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation (Letter). J Antimicrob Chemother (2009); 63: 623.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>623</start></extent></part><relatedItem type="host"><titleInfo><title>J Antimicrob Chemother</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>623</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit91"><titleInfo><title>4. Cardiovascular System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit92"><titleInfo><title>Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Agnelli G, Eriksson EL, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thromb Res (2009); 123: 488.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>488</start></extent></part><relatedItem type="host"><titleInfo><title>Thromb Res</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>488</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit93"><titleInfo><title>Papulopustular eruption after intravitreal bevacizumab (Avastin®) (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Amselem L, Diaz‐Llopis M, Garcia‐Delpech S, Montero J, Palomares P, Cervera E. Papulopustular eruption after intravitreal bevacizumab (Avastin®) (Letter). Acta Ophthalmol Scand (2009); 87: 110.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>110</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Ophthalmol Scand</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>110</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit94"><titleInfo><title>Stroke risk and antihypertensive drug treatment in the general population: The Japan arteriosclerosis longitudinal study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Asayama K, Ohkubo T, Yoshida S, Suzuki K, Metoki H, Harada A, Murakami Y, Ohashi Y, Ueshima H, Imai Y. Stroke risk and antihypertensive drug treatment in the general population: The Japan arteriosclerosis longitudinal study. J Hypertens (2009); 27: 357.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>357</start></extent></part><relatedItem type="host"><titleInfo><title>J Hypertens</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>357</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit95"><titleInfo><title>Use of antihypertensives and the risk of Parkinson disease (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ascherio A, Tanner CM. Use of antihypertensives and the risk of Parkinson disease (Letter). Neurology (2009); 72: 578.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>578</start></extent></part><relatedItem type="host"><titleInfo><title>Neurology</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>578</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit96"><titleInfo><title>Use and risk management of carvedilol for the treatment of heart failure in the community in England: Results from a modified prescription‐event monitoring study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aurich‐Barrera B, Wilton LV, Shakir SAW. Use and risk management of carvedilol for the treatment of heart failure in the community in England: Results from a modified prescription‐event monitoring study. Drug Saf (2009); 32: 43.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>43</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>43</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit97"><titleInfo><title>Is angiotensin‐converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Berns JS. Is angiotensin‐converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD?. Am J Kidney Dis (2009); 53: 192.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>192</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Kidney Dis</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>192</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit98"><titleInfo><title>Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: A cohort study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Blagojevic A, Delaney JAC, Levesque LE, Dendukuri N, Boivin JF, Brophy JM. Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: A cohort study. Pharmacoepidemiol Drug Saf (2009); 18: 362.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>362</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>362</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit99"><titleInfo><title>Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J (2009); 157: 352.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>352</start></extent></part><relatedItem type="host"><titleInfo><title>Am Heart J</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>352</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit100"><titleInfo><title>Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Boucher BJ. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone? (Letter). Diabet Med (2009); 26: 192.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>192</start></extent></part><relatedItem type="host"><titleInfo><title>Diabet Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>192</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit101"><titleInfo><title>Hepatotoxicity after intravenous amiodarone</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cataldi A, Gonella D, Robutti N, Siri M, Buonocore S, Odetti P. Hepatotoxicity after intravenous amiodarone. Aging Clin Exp Res (2008); 20: 593.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>593</start></extent></part><relatedItem type="host"><titleInfo><title>Aging Clin Exp Res</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>593</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit102"><titleInfo><title>Nicardipine‐induced acute hepatitis in an intensive care unit patient</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chaudhry M, Maqsood A, Diab‐Agha S, Rosenberg J. Nicardipine‐induced acute hepatitis in an intensive care unit patient. Am J Ther (2009); 16: 71.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>71</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>71</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit103"><titleInfo><title>Gingival hyperplasia and calcium channel blockers (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fourtounas C, Vlachojannis JG. Gingival hyperplasia and calcium channel blockers (Letter). J Clin Hypertens (2009); 11: 111.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>111</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Hypertens</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>111</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit104"><titleInfo><title>Efficacy and safety of ABT‐335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT‐335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol (2009); 103: 515.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>515</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Cardiol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>515</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit105"><titleInfo><title>Atorvastatin‐induced drug reaction with eosinophilia and systemic symptoms (DRESS) (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gressier L, Pruvost‐Balland C, Dubertret L, Viguier M. Atorvastatin‐induced drug reaction with eosinophilia and systemic symptoms (DRESS) (French, English Abstract). Ann Dermatol Venereol (2009); 136: 50.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>136</number></detail><extent unit="pages"><start>50</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Dermatol Venereol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>136</number></detail><extent unit="pages"><start>50</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit106"><titleInfo><title>The safety profile of tadalafil as prescribed in general practice in England: Results from a prescription‐event monitoring study involving 16 129 patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hazell L, Cornelius V, Wilton LV, Shakir SAW. The safety profile of tadalafil as prescribed in general practice in England: Results from a prescription‐event monitoring study involving 16 129 patients. BJU Int (2009); 103: 506.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>506</start></extent></part><relatedItem type="host"><titleInfo><title>BJU Int</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>506</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit107"><titleInfo><title>Antihypertensive treatment and risk of cardiovascular complications: Is the cure worse than the disease? (Editorial comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ibsen H. Antihypertensive treatment and risk of cardiovascular complications: Is the cure worse than the disease? (Editorial comment). J Hypertens (2009); 27: 221.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>221</start></extent></part><relatedItem type="host"><titleInfo><title>J Hypertens</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>221</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit108"><titleInfo><title>Causality assessment of liver injury after chronic oral amiodarone intake</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Llanos L, Moreu R, Peiro AM, Pascual S, Frances R, Such J, Horga JF, Perez‐Mateo M, Zapater P. Causality assessment of liver injury after chronic oral amiodarone intake. Pharmacoepidemiol Drug Saf (2009); 18: 291.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>291</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>291</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit109"><titleInfo><title>Utilisation of cardiovascular medicines in Republic of Srpska, Bosnia and Herzegovina, 5 years study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Markovic‐Pekovic V, Stoisavljevic‐Satara S, Skrbic R. Utilisation of cardiovascular medicines in Republic of Srpska, Bosnia and Herzegovina, 5 years study. Pharmacoepidemiol Drug Saf (2009); 18: 320.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>320</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>320</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit110"><titleInfo><title>Risk of community‐acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants: A population‐based case‐control study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJP, Gibson JE. Risk of community‐acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants: A population‐based case‐control study. Pharmacoepidemiol Drug Saf (2009); 18: 269.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>269</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>269</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit111"><titleInfo><title>Exaggerated benefits of rosuvastatin compared with other statins (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Qizilbash N. Exaggerated benefits of rosuvastatin compared with other statins (Letter). Pharmacoepidemiol Drug Saf (2009); 18: 425.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>425</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>425</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit112"><titleInfo><title>Delayed hypersensitivity to bosentan</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Romano A, Giovannetti A, Caruso C, Rosato E, Pierdominici M, Salsano F. Delayed hypersensitivity to bosentan. Allergy (2009); 64: 499.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>499</start></extent></part><relatedItem type="host"><titleInfo><title>Allergy</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>499</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit113"><titleInfo><title>Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rowan C, Brinker AD, Nourjah P, Chang J, Mosholder A, Barrett JS, Avigan M. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf (2009); 18: 301.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>301</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>301</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit114"><titleInfo><title>Short‐term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Song JH, Byeon SH, Lee SC, Koh HJ, Kwon OW. Short‐term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica (2009); 223: 85.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>223</number></detail><extent unit="pages"><start>85</start></extent></part><relatedItem type="host"><titleInfo><title>Ophthalmologica</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>223</number></detail><extent unit="pages"><start>85</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit115"><titleInfo><title>Cerebrovascular accidents in ranibizumab (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab (Letter). Ophthalmology (2009); 116: 362.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>362</start></extent></part><relatedItem type="host"><titleInfo><title>Ophthalmology</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>362</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit116"><titleInfo><title>5. CNS Depressive Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit117"><titleInfo><title>Predictor of mortality in suspected propofol infusion syndrome‐Brugada electrocardiographic pattern (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bebarta VS, Summers S. Predictor of mortality in suspected propofol infusion syndrome‐Brugada electrocardiographic pattern (Letter). Crit Care Med (2009); 37: 795.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>795</start></extent></part><relatedItem type="host"><titleInfo><title>Crit Care Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>795</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit118"><titleInfo><title>The prevalence, severity and impact of opioid‐induced bowel dysfunction: Results of a US and European patient survey (PROBE 1)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity and impact of opioid‐induced bowel dysfunction: Results of a US and European patient survey (PROBE 1). Pain Med (2009); 10: 35.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>35</start></extent></part><relatedItem type="host"><titleInfo><title>Pain Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>35</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit119"><titleInfo><title>Self‐limited febrile syndromes temporally associated with the use of propofol for sedation in gastrointestinal endoscopic procedures</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Blossom DB, Chen TH, Li J, Langer AJ, Carpenter LR, Glenshaw MT, Gould CV, Weltman A, Srinivasan A. Self‐limited febrile syndromes temporally associated with the use of propofol for sedation in gastrointestinal endoscopic procedures. Pharmacoepidemiol Drug Saf (2009); 18: 344.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>344</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>344</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit120"><titleInfo><title>Increase in tiagabine serum concentration with coadministration of gemfibrozil</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burstein AH, Boudreau EA, Theodore WH. Increase in tiagabine serum concentration with coadministration of gemfibrozil. Ann Pharmacother (2009); 43: 379.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>379</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>379</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit121"><titleInfo><title>The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: A report from the pediatric sedation research consortium</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cravero JP, Beach ML, Blike GT, Gallagher SM, Hertzog JH. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: A report from the pediatric sedation research consortium. Anesth Analg (2009); 108: 795.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>795</start></extent></part><relatedItem type="host"><titleInfo><title>Anesth Analg</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>795</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit122"><titleInfo><title>Interaction between rifampicin and methadone (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Waroux BL. Interaction between rifampicin and methadone (Letter). Acta Anaesthesiol Scand (2009); 53: 403.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>403</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Anaesthesiol Scand</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>403</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit123"><titleInfo><title>Oxycodone is associated with dose‐dependent QTc prolongation in patients and low‐affinity inhibiting of hERG activity in vitro</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fanoe S, Jensen GB, Sjogren P, Korsgaard MPG, Grunnet M. Oxycodone is associated with dose‐dependent QTc prolongation in patients and low‐affinity inhibiting of hERG activity in vitro. Br J Clin Pharmacol (2009); 67: 172.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>172</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>172</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit124"><titleInfo><title>Predictor of mortality in suspected propofol infusion syndrome‐Brugada electrocardiographic pattern (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fong J, Devlin JW. Predictor of mortality in suspected propofol infusion syndrome‐Brugada electrocardiographic pattern (Reply). Crit Care Med (2009); 37: 796.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>796</start></extent></part><relatedItem type="host"><titleInfo><title>Crit Care Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>796</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit125"><titleInfo><title>Interaction between rifampicin and methadone (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fredheim OMS, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Interaction between rifampicin and methadone (Reply). Acta Anaesthesiol Scand (2009); 53: 403.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>403</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Anaesthesiol Scand</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>403</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit126"><titleInfo><title>Probability of rash related to gabapentin therapy in a child</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gijsen VMGJ, De Wildt SN, Ito S. Probability of rash related to gabapentin therapy in a child. Ann Pharmacother (2009); 43: 387.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>387</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>387</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit127"><titleInfo><title>The potential use of intralipid to minimize propofol's cardiovascular effects (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gragasin FS, Davidge ST, Tsui BCH. The potential use of intralipid to minimize propofol's cardiovascular effects (Letter). Can J Anaesth (2009); 56: 170.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>170</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Anaesth</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>170</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit128"><titleInfo><title>Methemoglobinemia related to local anesthetics: A summary of 242 episodes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Guay J. Methemoglobinemia related to local anesthetics: A summary of 242 episodes. Anesth Analg (2009); 108: 837.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>837</start></extent></part><relatedItem type="host"><titleInfo><title>Anesth Analg</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>837</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit129"><titleInfo><title>Voriconazole drastically increases exposure to oral oxycodone</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hagelberg N, Nieminen T, Saari T, Neuvonen M, Neuvonen P, Laine K, Olkkola K. Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol (2009); 65: 263.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>263</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>263</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit130"><titleInfo><title>Safety and driving ability following low‐dose propofol sedation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Horiuchi A, Nakayama Y, Katsuyama Y, Ohmori S, Ichise Y, Tanaka N. Safety and driving ability following low‐dose propofol sedation. Digestion (2008); 78: 190.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>190</start></extent></part><relatedItem type="host"><titleInfo><title>Digestion</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>190</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit131"><titleInfo><title>Sedation medication received and adverse events related to sedation for brain MRI in children with and without developmental disabilities</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kannikeswaran N, Mahajan PV, Sethuraman U, Groebe A, Chen XG. Sedation medication received and adverse events related to sedation for brain MRI in children with and without developmental disabilities. Pediatr Anaesth (2009); 19: 250.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>250</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Anaesth</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>250</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit132"><titleInfo><title>Are migraineurs at increased risk of adverse drug responses?: A meta‐analytic comparison of topiramate‐related adverse drug reactions in epilepsy and migraine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses?: A meta‐analytic comparison of topiramate‐related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther (2009); 85: 283.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>283</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>283</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit133"><titleInfo><title>Gabapentin toxicity in renal failure: The importance of dose adjustment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Miller A, Price G. Gabapentin toxicity in renal failure: The importance of dose adjustment. Pain Med (2009); 10: 190.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>190</start></extent></part><relatedItem type="host"><titleInfo><title>Pain Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>190</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit134"><titleInfo><title>Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Neyns B, Hoorens A, Stupp R. Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. Acta Neurol Belg (2008); 108: 131.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>131</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Neurol Belg</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>131</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit135"><titleInfo><title>Toxic epidermal necrolysis in a child after carbamazepine dosage increment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sevketoglu E, Hatipoglu S, Akman M, Bicer S. Toxic epidermal necrolysis in a child after carbamazepine dosage increment. Pediatr Emerg Care (2009); 25: 93.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>93</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Emerg Care</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>93</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit136"><titleInfo><title>Acute intoxication with isopropanol (German, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Steinmann D, Faber T, Auwarter V, Heringhaus C. Acute intoxication with isopropanol (German, English Abstract). Anaesthesist (2009); 58: 149.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>149</start></extent></part><relatedItem type="host"><titleInfo><title>Anaesthesist</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>149</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit137"><titleInfo><title>Acetaminophen hepatotoxicity: Current management</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tan HH, Chang CY, Martin P. Acetaminophen hepatotoxicity: Current management. Mount Sinai J Med (2009); 76: 75.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>75</start></extent></part><relatedItem type="host"><titleInfo><title>Mount Sinai J Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>75</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit138"><titleInfo><title>Blood pressure reduction in hypertensive patients after withdrawal of effervescent medication</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ubeda A, Llopico J, Sanchez MT. Blood pressure reduction in hypertensive patients after withdrawal of effervescent medication. Pharmacoepidemiol Drug Saf (2009); 18: 417.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>417</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>417</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit139"><titleInfo><title>Phenytoin toxicity masquerading as motor neurone disease (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Veenith T, Jellema K, Pearce A, Goon S, Burnstein R. Phenytoin toxicity masquerading as motor neurone disease (Letter). Anaesthesia (2009); 64: 337.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>337</start></extent></part><relatedItem type="host"><titleInfo><title>Anaesthesia</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>337</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit140"><titleInfo><title>Banning benzocaine: Of bananas, bureaucrats, and blue men (Editorial comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Weinberg GL. Banning benzocaine: Of bananas, bureaucrats, and blue men (Editorial comment). Anesth Analg (2009); 108: 699.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>699</start></extent></part><relatedItem type="host"><titleInfo><title>Anesth Analg</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>699</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit141"><titleInfo><title>Efficacy and safety of levetiracetam (3,000 mg/day) as an adjunctive therapy in Chinese patients with refractory partial seizures</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Xiao Z, Li JM, Wang XF, Xiao F, Xi ZQ, Lv Y, Sun HB. Efficacy and safety of levetiracetam (3,000 mg/day) as an adjunctive therapy in Chinese patients with refractory partial seizures. Eur Neurol (2009); 61: 233.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>233</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Neurol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>233</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit142"><titleInfo><title>6. Non‐steroidal Anti‐inflammatory Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit143"><titleInfo><title>Severe hemolytic anemia and fatal hepatic failure associated with nimesulide (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Betrosian AP, Flevari K, Andrianakis I, Boudouri I, Douzinas EE. Severe hemolytic anemia and fatal hepatic failure associated with nimesulide (Letter). Dig Liver Dis (2009); 41: 80.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>80</start></extent></part><relatedItem type="host"><titleInfo><title>Dig Liver Dis</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>80</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit144"><titleInfo><title>Infliximab‐induced lupus‐like syndrome in a patient with ankylosing spondylitis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bodur H, Eser F, Konca S, Arikan S. Infliximab‐induced lupus‐like syndrome in a patient with ankylosing spondylitis. Rheumatol Int (2009); 29: 451.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>451</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatol Int</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>451</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit145"><titleInfo><title>Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Choi KH, Yoo WH. Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis. Rheumatol Int (2009); 29: 463.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>463</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatol Int</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>463</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit146"><titleInfo><title>Effect of non‐steroidal anti‐inflammatory drugs on non‐melanoma skin cancer incidence in the SKICAP‐AK trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Clouser MC, Roe DJ, Foote JA, Harris RB. Effect of non‐steroidal anti‐inflammatory drugs on non‐melanoma skin cancer incidence in the SKICAP‐AK trial. Pharmacoepidemiol Drug Saf (2009); 18: 276.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>276</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>276</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit147"><titleInfo><title>Cardiovascular and gastrointestinal risks of nonsteroidal antiinflammatory drugs revisited: Comment on the article by the American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Desai SP, Abramson SB, Buckley L, Crofford LJ, Cush JJ, Lovell DJ, Saag KG. Cardiovascular and gastrointestinal risks of nonsteroidal antiinflammatory drugs revisited: Comment on the article by the American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs (Reply). Arthritis Rheum (2009); 61: 285.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>285</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>285</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit148"><titleInfo><title>Restrictive cardiomyopathy secondary to hydroxychloroquine therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Manohar VA, Moder KG, Edwards WD, Klarich KW. Restrictive cardiomyopathy secondary to hydroxychloroquine therapy. J Rheumatol (2009); 36: 440.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>440</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>440</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit149"><titleInfo><title>Adalimumab‐induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Metyas SK, Tadros RM, Arkfeld DG. Adalimumab‐induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int (2009); 29: 437.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>437</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatol Int</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>437</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit150"><titleInfo><title>Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor‐associated periodic syndrome</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nedjai B, Hitman GA, Quillinan N, Coughlan RJ, Church L, McDermott MF, Turner MD. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor‐associated periodic syndrome. Arthritis Rheum (2009); 60: 619.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>619</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>619</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit151"><titleInfo><title>Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Paschou S, Voulgari PV, Vrabie IG, Saougou IG, Drosos AA. Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol (2009); 36: 351.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>351</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>351</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit152"><titleInfo><title>The CADEUS study: Burden of nonsteroidal anti‐inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rossignol M, Abouelfath A, Lassalle R, Merliere Y, Droz C, Begaud B, Depont F, Moride Y, Blin P, Moore N, Fourrier‐Reglat A. The CADEUS study: Burden of nonsteroidal anti‐inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers. Br J Clin Pharmacol (2009); 67: 118.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>118</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>118</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit153"><titleInfo><title>Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: Benefits versus risks</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rostom A, Moayyedi P, Hunt R. Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: Benefits versus risks. Aliment Pharmacol Ther (2009); 29: 481.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>481</start></extent></part><relatedItem type="host"><titleInfo><title>Aliment Pharmacol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>481</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit154"><titleInfo><title>Cardiovascular and gastrointestinal risks of nonsteroidal antiinflammatory drugs revisited: Comment on the article by the American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rothschild B. Cardiovascular and gastrointestinal risks of nonsteroidal antiinflammatory drugs revisited: Comment on the article by the American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs (Letter). Arthritis Rheum (2009); 61: 284.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>284</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>284</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit155"><titleInfo><title>Upper gastrointestinal ulcer in Japanese patients taking low‐dose aspirin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shiotani A, Sakakibara T, Yamanaka Y, Imamura H, Tarumi K, Manabe N, Kamada T, Kusunoki H, Hata J, Haruma K. Upper gastrointestinal ulcer in Japanese patients taking low‐dose aspirin. J Gastroenterol (2009); 44: 126.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>126</start></extent></part><relatedItem type="host"><titleInfo><title>J Gastroenterol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>126</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit156"><titleInfo><title>Aspirin desensitization in a patient with aspirin sensitivity and chronic idiopathic urticaria (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Slowik SM, Slavin RG. Aspirin desensitization in a patient with aspirin sensitivity and chronic idiopathic urticaria (Letter). Ann Allergy Asthma Immunol (2009); 102: 171.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>171</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Allergy Asthma Immunol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>171</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit157"><titleInfo><title>Infliximab‐induced acne: A new case and review of published reports (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Steels E, Peretz A, Vereecken P. Infliximab‐induced acne: A new case and review of published reports (Letter). J Dermatol Treat (2009); 20: 59.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>59</start></extent></part><relatedItem type="host"><titleInfo><title>J Dermatol Treat</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>59</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit158"><titleInfo><title>Efficacy and safety of TNFα antagonist therapy in patients with juvenile spondyloarthropathies</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNFα antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine (2009); 76: 24.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>24</start></extent></part><relatedItem type="host"><titleInfo><title>Joint Bone Spine</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>24</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit159"><titleInfo><title>7. CNS Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit160"><titleInfo><title>Opening the white boxes: The licensing documentation of efficacy and safety of psychotropic medicines for children</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aagaard L, Thirstrup S, Hansen EH. Opening the white boxes: The licensing documentation of efficacy and safety of psychotropic medicines for children. Pharmacoepidemiol Drug Saf (2009); 18: 401.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>401</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>401</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit161"><titleInfo><title>Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: A randomized, equivalent trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barragan‐Rodriguez L, Rodriguez‐Moran M, Guerrero‐Romero F. Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: A randomized, equivalent trial. Magnes Res (2008); 21: 218.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>218</start></extent></part><relatedItem type="host"><titleInfo><title>Magnes Res</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>218</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit162"><titleInfo><title>Association between risk factors for injurious falls and new benzodiazepine prescribing in elderly persons</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bartlett G, Abrahamowicz M, Grad R, Sylvestre MP, Tamblyn R. Association between risk factors for injurious falls and new benzodiazepine prescribing in elderly persons. BMC Fam Pract (2009); 10: 1.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Fam Pract</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit163"><titleInfo><title>Clozapine‐withdrawal catatonia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bastiampillai T, Forooziya F, Dhillon R. Clozapine‐withdrawal catatonia (Letter). Aust N Z J Psychiatry (2009); 43: 283.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>283</start></extent></part><relatedItem type="host"><titleInfo><title>Aust N Z J Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>283</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit164"><titleInfo><title>Microscopic colitis associated with celiac disease probably triggered by the administration of venlafaxine (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bechade D, Carmoi I, Bonnefoy S, Blondon H, Desrame J, Algayres JP. Microscopic colitis associated with celiac disease probably triggered by the administration of venlafaxine (French, English Abstract). Rev Med Interne (2009); 30: 74.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>74</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Med Interne</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>74</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit165"><titleInfo><title>The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)‐associated sexual side effects: Possible relationship to oral contraceptives</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bishop JR, Ellingrod VL, Akroush M, Moline J. The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)‐associated sexual side effects: Possible relationship to oral contraceptives. Hum Psychopharmacol Clin Exp (2009); 24: 207.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>207</start></extent></part><relatedItem type="host"><titleInfo><title>Hum Psychopharmacol Clin Exp</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>207</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit166"><titleInfo><title>Tolerability, pharmacokinetics and night‐time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Boyle J, Danjou P, Alexander R, Calder N, Gargano C, Agrawal N, Fu IO, McCrea JB, Murphy MG. Tolerability, pharmacokinetics and night‐time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects. Br J Clin Pharmacol (2009); 67: 180.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>180</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>180</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit167"><titleInfo><title>Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross‐titration with risperidone or olanzapine: Analysis of a randomized, open‐label study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross‐titration with risperidone or olanzapine: Analysis of a randomized, open‐label study. Schizophr Res (2009); 107: 218.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>218</start></extent></part><relatedItem type="host"><titleInfo><title>Schizophr Res</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>218</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit168"><titleInfo><title>Antidepressant medications and change in mammographic density in postmenopausal women</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chubak J, Bowles EJA, Terry MB, Trentham‐Dietz A, Buist DSM. Antidepressant medications and change in mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2009); 18: 676.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>676</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer Epidemiol Biomarkers Prev</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>676</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit169"><titleInfo><title>Mirtazapine induced nightmares in an adult male (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dang A, Garg G, Rataboli PV. Mirtazapine induced nightmares in an adult male (Letter). Br J Clin Pharmacol (2009); 67: 135.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>135</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>135</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit170"><titleInfo><title>Bupropion levels in breast milk for 4 mother‐infant pairs: More answers to lingering questions (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Davis MF, Miller HS, Nolan PE. Bupropion levels in breast milk for 4 mother‐infant pairs: More answers to lingering questions (Letter). J Clin Psychiatry (2009); 70: 297.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>297</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>297</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit171"><titleInfo><title>Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Faessel H, Ravva P, Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Clin Ther (2009); 31: 177.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>177</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>177</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit172"><titleInfo><title>Breastfeeding and antidepressants: Clinical dilemmas and expert perspectives</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Freeman MP. Breastfeeding and antidepressants: Clinical dilemmas and expert perspectives. J Clin Psychiatry (2009); 70: 291.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>291</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>291</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit173"><titleInfo><title>Antidepressant medications, neuroleptics, and prominent eye movements during NREM sleep</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Geyer JD, Carney PR, Dillard SC, Davis L, Ward LC. Antidepressant medications, neuroleptics, and prominent eye movements during NREM sleep. J Clin Neurophysiol (2009); 26: 39.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>39</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Neurophysiol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>39</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit174"><titleInfo><title>The effect of antipsychotic medication on sexual function and serum prolactin levels in community‐treated schizophrenic patients: Results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hanssens L, L'Italien G, Loze JY, Marcus RN, Pans M, Kerselaers W. The effect of antipsychotic medication on sexual function and serum prolactin levels in community‐treated schizophrenic patients: Results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry (2008); 8: 95.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>95</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Psychiatry</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>95</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit175"><titleInfo><title>Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second‐generation antipsychotic agents</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second‐generation antipsychotic agents. Am J Psychiatry (2009); 166: 345.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>345</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>345</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit176"><titleInfo><title>Starting insomnia treatment: The use of benzodiazepines versus z‐hypnotics. A prescription database study of predictors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hausken A, Furu K, Skurtveit S, Engeland A, Bramness J. Starting insomnia treatment: The use of benzodiazepines versus z‐hypnotics. A prescription database study of predictors. Eur J Clin Pharmacol (2009); 65: 295.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>295</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>295</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit177"><titleInfo><title>Are selective serotonin reuptake inhibitors a risk factor for adolescent suicide?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Healy D. Are selective serotonin reuptake inhibitors a risk factor for adolescent suicide?. Can J Psychiatry (2009); 54: 69.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>69</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>69</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit178"><titleInfo><title>Selective serotonin reuptake inhibitors and suicidality: A guide for the perplexed</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brent DA. Selective serotonin reuptake inhibitors and suicidality: A guide for the perplexed. Can J Psychiatry (2009); 54: 72.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>72</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>72</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit179"><titleInfo><title>Perplexity is our product</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Healy D. Perplexity is our product. Can J Psychiatry (2009); 54: 75.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>75</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>75</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit180"><titleInfo><title>Youth depression and suicide: Selective serotonin reuptake inhibitors treat the former and prevent the latter</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brent DA. Youth depression and suicide: Selective serotonin reuptake inhibitors treat the former and prevent the latter. Can J Psychiatry (2009); 54: 76.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>76</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>76</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit181"><titleInfo><title>Ziprasidone as an adjuvant for clozapine‐ or olanzapine‐associated medical morbidity in chronic schizophrenia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, Miley K, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC. Ziprasidone as an adjuvant for clozapine‐ or olanzapine‐associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol Clin Exp (2009); 24: 225.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>225</start></extent></part><relatedItem type="host"><titleInfo><title>Hum Psychopharmacol Clin Exp</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>225</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit182"><titleInfo><title>Cardiac‐related findings at autopsy in people with severe mental illness treated with clozapine or risperidone</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kelly DL, Wehring HJ, Linthicum J, Feldman S, McMahon RP, Love RC, Wagner T, Shim JC, Fowler DR. Cardiac‐related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Schizophr Res (2009); 107: 134.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>134</start></extent></part><relatedItem type="host"><titleInfo><title>Schizophr Res</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>134</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit183"><titleInfo><title>Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug‐induced fever</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kluge M, Schuld A, Schacht A, Himmerich H, Dalal MA, Wehmeier PM, Hinze‐Selch D, Kraus T, Dittmann RW, Pollmacher T. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug‐induced fever. Psychoneuroendocrinology (2009); 34: 118.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>118</start></extent></part><relatedItem type="host"><titleInfo><title>Psychoneuroendocrinology</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>118</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit184"><titleInfo><title>The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: A pooled analysis of 4 clinical trials</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kryzhanovskaya LA, Robertson‐Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: A pooled analysis of 4 clinical trials. J Clin Psychiatry (2009); 70: 247.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>247</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>247</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit185"><titleInfo><title>Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non‐cancer pain</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Manchikanti L, Manchikanti KN, Pampati V, Cash KA. Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non‐cancer pain. Pain Physician (2009); 12: 259.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>259</start></extent></part><relatedItem type="host"><titleInfo><title>Pain Physician</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>259</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit186"><titleInfo><title>Dosing patterns in Europe: Efficacy and safety of risperidone long‐acting injectable in doses of 25, 37.5 and 50 mg</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mauri MC, Turner M, Volonteri LS, Medori R, Maier W. Dosing patterns in Europe: Efficacy and safety of risperidone long‐acting injectable in doses of 25, 37.5 and 50 mg. Int J Psychiatry Clin Pract (2009); 13: 36.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>36</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Psychiatry Clin Pract</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>36</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit187"><titleInfo><title>The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double‐blind, placebo‐controlled trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double‐blind, placebo‐controlled trial. J Rheumatol (2009); 36: 398.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>398</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>398</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit188"><titleInfo><title>Obsessive‐compulsive disorder in UK clozapine‐treated schizophrenia and schizoaffective disorder: A cause for clinical concern</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mukhopadhaya K, Krishnaiah R, Taye T, Nigam A, Bailey AJ, Sivakumaran T, Fineberg NA. Obsessive‐compulsive disorder in UK clozapine‐treated schizophrenia and schizoaffective disorder: A cause for clinical concern. J Psychopharmacol (2009); 23: 6.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>6</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychopharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>6</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit189"><titleInfo><title>The use of a clinical utility index to compare insomnia compounds: A quantitative basis for benefit‐risk assessment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ouellet D, Werth J, Parekh N, Feltner D, McCarthy B, Lalonde RL. The use of a clinical utility index to compare insomnia compounds: A quantitative basis for benefit‐risk assessment. Clin Pharmacol Ther (2009); 85: 277.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>277</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>277</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit190"><titleInfo><title>Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schneeweiss S, Setoguchi S, Brookhart MA, Kaci L, Wang PS. Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs (2009); 23: 171.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>171</start></extent></part><relatedItem type="host"><titleInfo><title>CNS Drugs</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>171</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit191"><titleInfo><title>Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: Case reports and a review of the literature</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: Case reports and a review of the literature. Psychosomatics (2009); 50: 8.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>8</start></extent></part><relatedItem type="host"><titleInfo><title>Psychosomatics</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>8</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit192"><titleInfo><title>A case of mirtazapine‐induced spontaneous orgasms in a female patient</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shalev H, Ben‐Zion I, Shiber A. A case of mirtazapine‐induced spontaneous orgasms in a female patient. J Psychopharmacol (2009); 23: 109.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>109</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychopharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>109</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit193"><titleInfo><title>Zolpidem‐induced amnesia and somnambulism: Rare occurences?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsai JH, Yang PC, Chen CC, Chung WL, Tang TC, Wang SY, Liu JK. Zolpidem‐induced amnesia and somnambulism: Rare occurences?. Eur Neuropsychopharmacol (2009); 19: 74.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>74</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Neuropsychopharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>74</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit194"><titleInfo><title>Is second‐generation antipsychotic‐induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tschoner A, Engl J, Rettenbacher MA, Kaser S, Ott HW, Fleischhacker WW, Patsch JR, Edenbichler CF. Is second‐generation antipsychotic‐induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study (Letter). J Clin Psychiatry (2009); 70: 293.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>293</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>293</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit195"><titleInfo><title>Efficacy and safety of lamotrigine as add‐on treatment to lithium in bipolar depression: A multicenter, double‐blind, placebo‐controlled trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van der Loos MLM, Mulder PGH, Hartong EGTM, Blom MBJ, Vergouwen AC, De Keyzer HJUEM, Notten PJH, Luteijn ML, Timmermans MA, Vieta E, Nolen WA. Efficacy and safety of lamotrigine as add‐on treatment to lithium in bipolar depression: A multicenter, double‐blind, placebo‐controlled trial. J Clin Psychiatry (2009); 70: 223.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>223</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>223</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit196"><titleInfo><title>Use of benzodiazepines, depressive symptoms and cognitive function in old age</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van Vliet P, Van der Mast RC, Van den Broek M, Westendorp RGJ, De Craen AJM. Use of benzodiazepines, depressive symptoms and cognitive function in old age. Int J Geriatr Psychiatry (2009); 24: 500.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>500</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Geriatr Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>500</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit197"><titleInfo><title>No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Walitza S, Kampf K, Artamonov N, Romanos M, Gnana Oli R, Wirth S, Warnke A, Gerlach M, Stopper H. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy. Toxicol Lett (2009); 184: 38.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>184</number></detail><extent unit="pages"><start>38</start></extent></part><relatedItem type="host"><titleInfo><title>Toxicol Lett</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>184</number></detail><extent unit="pages"><start>38</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit198"><titleInfo><title>Antidepressant medication use and breast cancer risk</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wernli KJ, Hampton JM, Trentham‐Dietz A, Newcomb PA. Antidepressant medication use and breast cancer risk. Pharmacoepidemiol Drug Saf (2009); 18: 284.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>284</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>284</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit199"><titleInfo><title>Fluctuating plasma levels of the active moiety of risperidone is related to occurrence of extrapyramidal symptoms</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yoshimura R, Ueda N, Ikenouch‐Sugita A, Umene‐Nakano W, Hori H, Kakihara S, Nakamura J. Fluctuating plasma levels of the active moiety of risperidone is related to occurrence of extrapyramidal symptoms. Int J Psychiatry Clin Pract (2009); 13: 21.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>21</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Psychiatry Clin Pract</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>21</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit200"><titleInfo><title>8. Anti‐neoplastic Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit201"><titleInfo><title>Docetaxel‐induced skin toxicity (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Arwert L. Docetaxel‐induced skin toxicity (Letter). Neth J Med (2009); 67: 33.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>33</start></extent></part><relatedItem type="host"><titleInfo><title>Neth J Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>33</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit202"><titleInfo><title>Pharmacokinetics, a main actor in a many‐sided approach to severe 5‐FU toxicity prediction (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bocci G, Di Paolo A, Barbara C, Masi G, Fornaro L, Loupakis F, Allegrini G, Falcone A, Del Tacca M, Danesi R. Pharmacokinetics, a main actor in a many‐sided approach to severe 5‐FU toxicity prediction (Letter). Br J Clin Pharmacol (2009); 67: 132.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>132</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>132</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit203"><titleInfo><title>Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brizzi MP, Sculli CM, Ragni F, Porpiglia F, Tampellini M, Gorzegno G, Priola AM, Dogliotti L, Berruti A. Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma (Letter). Ann Oncol (2009); 20: 389.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>389</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Oncol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>389</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit204"><titleInfo><title>Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cerny J, Hassan A, Smith C, Piperdi B. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer (2009); 8: 55.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>55</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Colorectal Cancer</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>55</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit205"><titleInfo><title>Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chamberlain MC. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence (Letter). Neurology (2009); 72: 772.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>772</start></extent></part><relatedItem type="host"><titleInfo><title>Neurology</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>772</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit206"><titleInfo><title>Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathy. J Peripher Nerv Syst (2008); 13: 275.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>275</start></extent></part><relatedItem type="host"><titleInfo><title>J Peripher Nerv Syst</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>275</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit207"><titleInfo><title>Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology Basel (2009); 76: 209.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>209</start></extent></part><relatedItem type="host"><titleInfo><title>Oncology Basel</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>209</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit208"><titleInfo><title>Cognitive effects of chemotherapy in post‐menopausal breast cancer patients 1 year after treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of chemotherapy in post‐menopausal breast cancer patients 1 year after treatment. Psychooncology (2009); 18: 134.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>134</start></extent></part><relatedItem type="host"><titleInfo><title>Psychooncology</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>134</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit209"><titleInfo><title>Neurotoxicity during ifosfamide treatment in children</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Di Cataido A, Astuto M, Rizzo G, Bertuna G, Russo G, Incorpora G. Neurotoxicity during ifosfamide treatment in children. Med Sci Monit (2009); 15: CS22.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>CS22</start></extent></part><relatedItem type="host"><titleInfo><title>Med Sci Monit</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>CS22</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit210"><titleInfo><title>Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Donadio C, Lucchesi A, Ardini M, Cosio S, Fanucchi A, Gadducci A. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer. Ther Drug Monit (2009); 31: 63.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>63</start></extent></part><relatedItem type="host"><titleInfo><title>Ther Drug Monit</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>63</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit211"><titleInfo><title>Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer (2009); 7: 20.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>20</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Genitourin Cancer</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>20</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit212"><titleInfo><title>A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Duffy SR, Distler W, Howell A, Cuzick J, Baum M. A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. Am J Obstet Gynecol (2009); 200: 80.e1.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>200</number></detail><extent unit="pages"><start>80.e1</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Obstet Gynecol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>200</number></detail><extent unit="pages"><start>80.e1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit213"><titleInfo><title>Sorafenib and surgical complications: A case report of adverse reaction to sorafenib during treatment for renal cell carcinoma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Eng FCS, Easson AM, Szentgyorgyi E, Knox JJ. Sorafenib and surgical complications: A case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. Eur J Surg Oncol (2009); 35: 219.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>219</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Surg Oncol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>219</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit214"><titleInfo><title>Epidemiologic studies are needed to clarify whether dental modalities could be predictors of bisphosphonate osteonecrosis of the jaw in breast cancer patients (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Giordano SH. Epidemiologic studies are needed to clarify whether dental modalities could be predictors of bisphosphonate osteonecrosis of the jaw in breast cancer patients (Reply). Oncologist (2009); 14: 103.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>103</start></extent></part><relatedItem type="host"><titleInfo><title>Oncologist</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>103</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit215"><titleInfo><title>Multicenter randomized open‐label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose‐intensified carboplatin plus etoposide plus lenograstim in small‐cell lung cancer in “extensive disease” stage</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heigener DF, Manegold C, Jager E, Saal JG, Zuna I, Gatzemeier U. Multicenter randomized open‐label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose‐intensified carboplatin plus etoposide plus lenograstim in small‐cell lung cancer in “extensive disease” stage. Am J Clin Oncol (2009); 32: 61.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>61</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Clin Oncol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>61</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit216"><titleInfo><title>EBV‐associated diffuse large B‐cell lymphoma in a psoriatic treated with methotrexate</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hsiao SC, Ichinohasama R, Lin SH, Liao YL, Chang ST, Cho CY, Chuang SS. EBV‐associated diffuse large B‐cell lymphoma in a psoriatic treated with methotrexate. Pathol Res Pract (2009); 205: 43.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>205</number></detail><extent unit="pages"><start>43</start></extent></part><relatedItem type="host"><titleInfo><title>Pathol Res Pract</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>205</number></detail><extent unit="pages"><start>43</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit217"><titleInfo><title>Safety and efficacy of tibolone in breast‐cancer patients with vasomotor symptoms: A double‐blind, randomised, non‐inferiority trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kenemans P, Bundred NJ, Foidart JM, Kubista E, Von Schoultz B, Sismondi P, Vassilopoulou‐Sellin R, Yip CH, Egberts J, Mol‐Arts M, Mulder R, Van Os S, Beckmann MW. Safety and efficacy of tibolone in breast‐cancer patients with vasomotor symptoms: A double‐blind, randomised, non‐inferiority trial. Lancet Oncol (2009); 10: 135.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>135</start></extent></part><relatedItem type="host"><titleInfo><title>Lancet Oncol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>135</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit218"><titleInfo><title>Epidemiologic studies are needed to clarify whether dental modalities could be predictors of bisphosphonate osteonecrosis of the jaw in breast cancer patients (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kyrgidis A, Andreadis C. Epidemiologic studies are needed to clarify whether dental modalities could be predictors of bisphosphonate osteonecrosis of the jaw in breast cancer patients (Letter). Oncologist (2009); 14: 101.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>101</start></extent></part><relatedItem type="host"><titleInfo><title>Oncologist</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>101</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit219"><titleInfo><title>Regular dental check‐ups could be of benefit for patients receiving intravenous bisphosphonates. Regarding ‘risks and benefits of bisphosphonates’ (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kyrgidis A, Triaridis S. Regular dental check‐ups could be of benefit for patients receiving intravenous bisphosphonates. Regarding ‘risks and benefits of bisphosphonates’ (Letter). Br J Cancer (2009); 100: 670.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>670</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Cancer</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>670</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit220"><titleInfo><title>Role of a pre‐existing neuropathy on the course of bortezomib‐induced peripheral neurotoxicity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lanzani F, Mattavelli L, Frigeni B, Rossini F, Cammarota S, Petro D, Jann S, Cavaletti G. Role of a pre‐existing neuropathy on the course of bortezomib‐induced peripheral neurotoxicity. J Peripher Nerv Syst (2008); 13: 267.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>267</start></extent></part><relatedItem type="host"><titleInfo><title>J Peripher Nerv Syst</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>267</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit221"><titleInfo><title>Chemotherapy‐induced recall of cetuximab and radiation skin reaction (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Law AB, Junor EJ. Chemotherapy‐induced recall of cetuximab and radiation skin reaction (Letter). Clin Oncol UK (2009); 21: 77.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>77</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Oncol UK</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>77</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit222"><titleInfo><title>Pre‐treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liu LQ, Fiorentino L, Natarajan L, Parker BA, Mills PJ, Sadler GR, Dimsdale JE, Rissling M, He F, Ancoli‐Israel S. Pre‐treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. Psychooncology (2009); 18: 187.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>187</start></extent></part><relatedItem type="host"><titleInfo><title>Psychooncology</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>187</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit223"><titleInfo><title>Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Magne N, Castadot P, Chargari C, Di Leo A, Philippson C, Van Houtte P. Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. Radiother Oncol (2009); 90: 116.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>116</start></extent></part><relatedItem type="host"><titleInfo><title>Radiother Oncol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>116</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit224"><titleInfo><title>Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity and patterns of recurrence (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mrugala MM. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity and patterns of recurrence (Letter). Neurology (2009); 72: 773.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>773</start></extent></part><relatedItem type="host"><titleInfo><title>Neurology</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>773</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit225"><titleInfo><title>Bilateral vocal cord paralysis following treatment with vincristine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Naithani R, Dolai TK, Kumar R. Bilateral vocal cord paralysis following treatment with vincristine. Indian Pediatr (2009); 46: 68.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>68</start></extent></part><relatedItem type="host"><titleInfo><title>Indian Pediatr</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>68</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit226"><titleInfo><title>Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Norden AD, Young GS, Wen PY. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence (Reply). Neurology (2009); 72: 773.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>773</start></extent></part><relatedItem type="host"><titleInfo><title>Neurology</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>773</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit227"><titleInfo><title>Successful treatment of mitomycin‐induced thrombotic thrombocytopenic purpura with rituximab (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Onitilo AA, Engel JM, Clouse LH, Gerndt KM. Successful treatment of mitomycin‐induced thrombotic thrombocytopenic purpura with rituximab (Letter). J Vasc Interv Radiol (2009); 20: 275.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>275</start></extent></part><relatedItem type="host"><titleInfo><title>J Vasc Interv Radiol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>275</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit228"><titleInfo><title>Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose‐modification guideline</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben‐Yehuda D, Lonial S, Goldschmidt H, Reece D, Blade J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose‐modification guideline. Br J Haematol (2009); 144: 895.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>895</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Haematol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>895</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit229"><titleInfo><title>Oxaliplatin‐mediated autoimmune thrombocytopenia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Saif MW, The A, Ledbetter L. Oxaliplatin‐mediated autoimmune thrombocytopenia. Clin Colorectal Cancer (2009); 8: 61.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>61</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Colorectal Cancer</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>61</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit230"><titleInfo><title>Bowel perforation in non‐small cell lung cancer after bevacizumab therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U. Bowel perforation in non‐small cell lung cancer after bevacizumab therapy. Invest New Drugs (2009); 27: 184.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>184</start></extent></part><relatedItem type="host"><titleInfo><title>Invest New Drugs</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>184</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit231"><titleInfo><title>Peritoneal tuberculosis after imatinib therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Senn L, Kovacsovics T, Tarr PE, Meylan P. Peritoneal tuberculosis after imatinib therapy (Letter). Arch Intern Med (2009); 169: 312.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>169</number></detail><extent unit="pages"><start>312</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Intern Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>169</number></detail><extent unit="pages"><start>312</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit232"><titleInfo><title>Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: A retrospective single‐institution study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shaffer R, Tyldesley S, Rolles M, Chia S, Mohamed I. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: A retrospective single‐institution study. Radiother Oncol (2009); 90: 122.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>122</start></extent></part><relatedItem type="host"><titleInfo><title>Radiother Oncol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>122</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit233"><titleInfo><title>Bortezomib‐induced neurogenic bladder in patients with multiple myeloma (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shimura K, Shimazaki C, Taniguchi K, Inaba T, Horiike S, Taniwaki M. Bortezomib‐induced neurogenic bladder in patients with multiple myeloma (Letter). Ann Hematol (2009); 88: 383.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>383</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Hematol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>383</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit234"><titleInfo><title>An open‐label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stephenson JJ, Gregory C, Burris H, Larson T, Verma U, Cohn A, Crawford J, Cohen RB, Martin J, Lum P, Yang X, Amado RG. An open‐label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors. Clin Colorectal Cancer (2009); 8: 29.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>29</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Colorectal Cancer</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>29</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit235"><titleInfo><title>Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tanvetyanon T, Murtagh R, Bepler G. Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab (Letter). J Thorac Oncol (2009); 4: 268.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>268</start></extent></part><relatedItem type="host"><titleInfo><title>J Thorac Oncol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>268</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit236"><titleInfo><title>Gemcitabine‐induced retinopathy in a diabetic patient (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tran THC, Desauw C, Rose C. Gemcitabine‐induced retinopathy in a diabetic patient (Letter). Acta Ophthalmol Scand (2009); 87: 114.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>114</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Ophthalmol Scand</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>114</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit237"><titleInfo><title>Safety and clinical efficacy of a new 6‐month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tunn UW, Wiedey K. Safety and clinical efficacy of a new 6‐month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. Prostate Cancer Prostatic Dis (2009); 12: 83.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>83</start></extent></part><relatedItem type="host"><titleInfo><title>Prostate Cancer Prostatic Dis</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>83</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit238"><titleInfo><title>9. Haematological Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit239"><titleInfo><title>The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Breuer T, Martin K, Wilhelm M, Wiesner G, Schreiber C, Hess J, Lange R, Tassani P. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg (2009); 35: 167.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>167</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Cardiothorac Surg</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>167</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit240"><titleInfo><title>Life‐threatening retroperitoneal bleeding due to warfarin—drug interactions</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chan TYK. Life‐threatening retroperitoneal bleeding due to warfarin—drug interactions. Pharmacoepidemiol Drug Saf (2009); 18: 420.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>420</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>420</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit241"><titleInfo><title>Heparin‐induced thrombocytopenia: What clinicians need to know</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chong BH, Isaacs A. Heparin‐induced thrombocytopenia: What clinicians need to know. Thromb Haemost (2009); 101: 279.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>279</start></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>279</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit242"><titleInfo><title>Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: A meta‐analysis of epidemiologic studies</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gagne JJ, Griesdale DEG, Schneeweiss S. Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: A meta‐analysis of epidemiologic studies. Pharmacoepidemiol Drug Saf (2009); 18: 259.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>259</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>259</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit243"><titleInfo><title>Safety and efficacy of a surgeon‐prepared gelatin hemostatic agent compared with FloSeal for hemostasis in laparoscopic partial nephrectomy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Guzzo TJ, Pollock RA, Forney A, Aggarwal P, Matlaga BR, Allaf ME. Safety and efficacy of a surgeon‐prepared gelatin hemostatic agent compared with FloSeal for hemostasis in laparoscopic partial nephrectomy. J Endourol (2009); 23: 279.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>279</start></extent></part><relatedItem type="host"><titleInfo><title>J Endourol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>279</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit244"><titleInfo><title>Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA (2009); 301: 937.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>301</number></detail><extent unit="pages"><start>937</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>301</number></detail><extent unit="pages"><start>937</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit245"><titleInfo><title>Aggrenox (Asasantin retard)‐induced Stevens‐Johnson syndrome (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jao T, Tsai TH, Jeng JS. Aggrenox (Asasantin retard)‐induced Stevens‐Johnson syndrome (Letter). Br J Clin Pharmacol (2009); 67: 264.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>264</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>264</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit246"><titleInfo><title>Warfarin‐antiretroviral interactions</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liedtke MD, Rathbun RC. Warfarin‐antiretroviral interactions. Ann Pharmacother (2009); 43: 322.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>322</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>322</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit247"><titleInfo><title>Efficacy and safety of once‐weekly intravenous epoetin α in maintaining hemoglobin levels in hemodialysis patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Locatelli F, Villa G, Messa P, Filippini A, Cannella G, De Ferrari G, Naso A, Rossi E, Formica M, Lombardi L, Rotolo U, Conte F. Efficacy and safety of once‐weekly intravenous epoetin α in maintaining hemoglobin levels in hemodialysis patients. J Nephrol (2008); 21: 412.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>412</start></extent></part><relatedItem type="host"><titleInfo><title>J Nephrol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>412</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit248"><titleInfo><title>Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: A retrospective analysis of dosing, efficacy and safety outcomes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Masud F, Bostan F, Chi E, Pass SE, Sarnir H, Stuebing K, Liebl MG. Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: A retrospective analysis of dosing, efficacy and safety outcomes. J Cardiothorac Vasc Anesth (2009); 23: 28.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>28</start></extent></part><relatedItem type="host"><titleInfo><title>J Cardiothorac Vasc Anesth</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>28</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit249"><titleInfo><title>Risk of clinically relevant bleeding in warfarin‐treated patients—influence of SSRI treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wallerstedt SM, Gleerup H, Sundstrom A, Stigendal L, Ny L. Risk of clinically relevant bleeding in warfarin‐treated patients—influence of SSRI treatment. Pharmacoepidemiol Drug Saf (2009); 18: 412.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>412</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>412</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit250"><titleInfo><title>10. Neuroregulator‐Blocking Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit251"><titleInfo><title>Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: A multicentre, open‐label study in Spain</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Valero A, De la Torre F, Castillo JA, Rivas P, Del Cuvillo A, Antepara I, Borja J, Donado E, Mola O, Izquierdo I. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: A multicentre, open‐label study in Spain. Drug Saf (2009); 32: 33.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>33</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>33</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit252"><titleInfo><title>Seizure associated with palonosetron (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zambelli A, Sagrada P, Pavesi L. Seizure associated with palonosetron (Letter). Support Care Cancer (2009); 17: 217.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>217</start></extent></part><relatedItem type="host"><titleInfo><title>Support Care Cancer</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>217</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit253"><titleInfo><title>11. Dermatological Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit254"><titleInfo><title>Efalizumab‐associated papular psoriasis: An adverse reaction to efalizumab in three cases</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Antonucci A, Bardazzi F, Balestri R, Patrizi A. Efalizumab‐associated papular psoriasis: An adverse reaction to efalizumab in three cases. J Dermatol Treat (2009); 20: 61.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>61</start></extent></part><relatedItem type="host"><titleInfo><title>J Dermatol Treat</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>61</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit255"><titleInfo><title>Serum sickness‐like reaction associated with efalizumab</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ashraf‐Benson S, Wall GC, Veach LA. Serum sickness‐like reaction associated with efalizumab. Ann Pharmacother (2009); 43: 383.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>383</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>383</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit256"><titleInfo><title>Acute acne flare following isotretinoin administration: Potential protective role of low starting dose (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Borghi A, Mantovani L, Minghetti S, Virgili A, Bettoli V. Acute acne flare following isotretinoin administration: Potential protective role of low starting dose (Letter). Dermatology (2009); 218: 178.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>218</number></detail><extent unit="pages"><start>178</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>218</number></detail><extent unit="pages"><start>178</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit257"><titleInfo><title>Palifermin‐associated papular eruption</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">King B, Knopp E, Galan A, Nuovo G, Tigelaar R, McNiff J. Palifermin‐associated papular eruption. Arch Dermatol (2009); 145: 179.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>145</number></detail><extent unit="pages"><start>179</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>145</number></detail><extent unit="pages"><start>179</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit258"><titleInfo><title>Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kop EN, Korver JEM, Van Ruysevelt D, De Jong EMGJ, Van der Valk PG, Van de Kerkhof P. Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment. J Dermatol Treat (2009); 20: 67.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>67</start></extent></part><relatedItem type="host"><titleInfo><title>J Dermatol Treat</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>67</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit259"><titleInfo><title>12. Immunosuppressive Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit260"><titleInfo><title>Severe hyponatraemia secondary to cure of cyclophosphamide (about three cases) (Letter) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alilou M, Awab A, Zarouf M, El Moussaoui R, El Hijri A, Azzouzi A, Slaoui A. Severe hyponatraemia secondary to cure of cyclophosphamide (about three cases) (Letter) (French). Ann Fr Anesth Reanim (2009); 28: 103.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>103</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Fr Anesth Reanim</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>103</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit261"><titleInfo><title>Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double‐blind, methotrexate‐controlled study of patients with active rheumatoid arthritis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos‐Vargas R, DeLora P, Zimany K, Travers H, Caulfield JP. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double‐blind, methotrexate‐controlled study of patients with active rheumatoid arthritis. Arthritis Rheum (2009); 60: 335.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>335</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>335</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit262"><titleInfo><title>Conversion to everolimus monotherapy in maintenance liver transplantation: Feasibility, safety, and impact on renal function</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E, Ducci J, Caneschi F, Coletti L, Campani D, Filipponi F. Conversion to everolimus monotherapy in maintenance liver transplantation: Feasibility, safety, and impact on renal function. Transpl Int (2009); 22: 279.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>279</start></extent></part><relatedItem type="host"><titleInfo><title>Transpl Int</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>279</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit263"><titleInfo><title>Distribution of TPMT risk alleles for thiopurine toxicity in the Israeli population</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Efrati E, Adler L, Krivoy N, Sprecher E. Distribution of TPMT risk alleles for thiopurine toxicity in the Israeli population. Eur J Clin Pharmacol (2009); 65: 257.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>257</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>257</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit264"><titleInfo><title>Temsirolimus‐induced glomerulopathy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Izzedine H, Boostandoot E, Spano JP, Bardier A, Khayat D. Temsirolimus‐induced glomerulopathy. Oncology Basel (2009); 76: 170.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>170</start></extent></part><relatedItem type="host"><titleInfo><title>Oncology Basel</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>170</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit265"><titleInfo><title>Factors associated with proteinuria in renal transplant recipients treated with sirolimus</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liew A, Chiang GSC, Vathsala A. Factors associated with proteinuria in renal transplant recipients treated with sirolimus. Transpl Int (2009); 22: 313.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>313</start></extent></part><relatedItem type="host"><titleInfo><title>Transpl Int</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>313</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit266"><titleInfo><title>Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard‐dose or reduced‐dose tacrolimus in liver transplant recipients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nashan B, Saliba F, Durand F, Barcena R, Herrero JI, Mentha G, Neuhaus P, Bowles M, Patch D, Bernardos A, Klempnauer J, Bouw R, Ives J, Mamelok R, McKay D, Truman M, Marotta P. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard‐dose or reduced‐dose tacrolimus in liver transplant recipients. Liver Transplant (2009); 15: 136.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>136</start></extent></part><relatedItem type="host"><titleInfo><title>Liver Transplant</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>136</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit267"><titleInfo><title>A comparison of mycophenolate use in Australia and Northern Europe, and the impact on the pharmaceutical benefits scheme</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Staatz CE, Smith AJ, Tett SE. A comparison of mycophenolate use in Australia and Northern Europe, and the impact on the pharmaceutical benefits scheme. Pharmacoepidemiol Drug Saf (2009); 18: 386.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>386</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>386</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit268"><titleInfo><title>Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Suzuki K, Kameda H, Amano K, Nagasawa H, Takei H, Sekiguchi N, Nishi E, Ogawa H, Tsuzaka K, Takeuchi T. Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. Rheumatol Int (2009); 29: 431.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>431</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatol Int</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>431</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit269"><titleInfo><title>Local application of tacrolimus in distal colitis: Feasible and safe</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van Dieren JM, Van Bodegraven AA, Kuipers EJ, Bakker EN, Poen AC, Van Dekken H, Nieuwenhuis EES, Van der Woude CJ. Local application of tacrolimus in distal colitis: Feasible and safe. Inflamm Bowel Dis (2009); 15: 193.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>193</start></extent></part><relatedItem type="host"><titleInfo><title>Inflamm Bowel Dis</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>193</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit270"><titleInfo><title>Relationships between thiopurine S‐methyltransferase polymorphism and azathioprine‐related adverse drug reactions in Chinese renal transplant recipients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Xin HW, Xiong H, Wu XC, Li Q, Xiong L, Yu AR. Relationships between thiopurine S‐methyltransferase polymorphism and azathioprine‐related adverse drug reactions in Chinese renal transplant recipients. Eur J Clin Pharmacol (2009); 65: 249.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>249</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>249</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit271"><titleInfo><title>13. Autonomic Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit272"><titleInfo><title>Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Braun M, Cawello W, Boekens H, Horstmann R. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol (2009); 67: 209.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>209</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>209</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit273"><titleInfo><title>Allergic contact dermatitis from timolol complicating choroidal melanoma‐related glaucoma (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Buquicchio R, Foti C, Cassano N, Ventura M, Vena GA. Allergic contact dermatitis from timolol complicating choroidal melanoma‐related glaucoma (Letter). Eur J Dermatol (2009); 19: 74.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>74</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Dermatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>74</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit274"><titleInfo><title>The use and potential abuse of anticholinergic antiparkinson drugs in Norway: A pharmacoepidemiological study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gjerden P, Bramness JG, Slordal L. The use and potential abuse of anticholinergic antiparkinson drugs in Norway: A pharmacoepidemiological study. Br J Clin Pharmacol (2009); 67: 228.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>228</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>228</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit275"><titleInfo><title>Toxic corneal oedema associated with amantadine use</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pond A, Lee MS, Hardten DR, Harrison AR, Krachmer JH. Toxic corneal oedema associated with amantadine use. Br J Ophthalmol (2009); 93: 281.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>281</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Ophthalmol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>281</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit276"><titleInfo><title>Pleural effusion caused by pergolide (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Salvado M, Barreiro B, Gonzalez C. Pleural effusion caused by pergolide (Letter) (Spanish). Arch Bronconeumol (2009); 45: 62.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>62</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Bronconeumol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>62</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit277"><titleInfo><title>14. Respiratory System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit278"><titleInfo><title>Rate of suicide in patients taking montelukast</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jick H, Hagberg KW, Egger P. Rate of suicide in patients taking montelukast. Pharmacotherapy (2009); 29: 165.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>165</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>165</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit279"><titleInfo><title>Safety and efficacy of inhaled corticosteroids (ICS) in children with asthma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Petrisko MA, Skoner JD, Skoner DP. Safety and efficacy of inhaled corticosteroids (ICS) in children with asthma. J Asthma (2008); 45: 1.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>J Asthma</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit280"><titleInfo><title>Long‐term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: A meta‐analysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Singh S, Amin AV, Loke YK. Long‐term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: A meta‐analysis. Arch Intern Med (2009); 169: 219.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>169</number></detail><extent unit="pages"><start>219</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Intern Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>169</number></detail><extent unit="pages"><start>219</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit281"><titleInfo><title>Adherence to diagnostic guidelines and quality indicators in asthma and COPD in Swedish primary care</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Weidinger P, Nilsson JLG, Lindblad U. Adherence to diagnostic guidelines and quality indicators in asthma and COPD in Swedish primary care. Pharmacoepidemiol Drug Saf (2009); 18: 393.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>393</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>393</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit282"><titleInfo><title>15. Neuromuscular Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit283"><titleInfo><title>Dystonic reaction after Botox injection under nitrous oxide/oxygen and sevoflurane anesthesia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Abdallah C, Hannallah R. Dystonic reaction after Botox injection under nitrous oxide/oxygen and sevoflurane anesthesia (Letter). Pediatr Anaesth (2009); 19: 269.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>269</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Anaesth</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>269</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit284"><titleInfo><title>Outcome predictors, efficacy and safety of Botox and Dysport in the long‐term treatment of hemifacial spasm</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Outcome predictors, efficacy and safety of Botox and Dysport in the long‐term treatment of hemifacial spasm. Eur J Neurol (2009); 16: 392.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>392</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Neurol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>392</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit285"><titleInfo><title>16. Reproductive System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit286"><titleInfo><title>Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: A cross‐over study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fleischer K, Van Vliet HA, Rosendaal FR, Rosing J, Tchaikovski S, Helmerhorst FM. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: A cross‐over study. Thromb Res (2009); 123: 429.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>429</start></extent></part><relatedItem type="host"><titleInfo><title>Thromb Res</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>429</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit287"><titleInfo><title>Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: A population‐based case‐control study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koomen ER, Joosse A, Herings RMC, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: A population‐based case‐control study. Ann Oncol (2009); 20: 358.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>358</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Oncol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>358</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit288"><titleInfo><title>A pilot observational study to assess the safety and efficacy of menoprogen for the management of menopausal symptoms in Chinese women</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liu D, Lu Y, Ma H, Wei RC, Li JR, Fang J, Mahady GB. A pilot observational study to assess the safety and efficacy of menoprogen for the management of menopausal symptoms in Chinese women. J Altern Complement Med (2009); 15: 79.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>79</start></extent></part><relatedItem type="host"><titleInfo><title>J Altern Complement Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>79</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit289"><titleInfo><title>A case‐control study of oral contraceptive use and incident breast cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rosenberg L, Zhang YQ, Coogan PF, Strom BL, Palmer JR. A case‐control study of oral contraceptive use and incident breast cancer. Am J Epidemiol (2009); 169: 473.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>169</number></detail><extent unit="pages"><start>473</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Epidemiol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>169</number></detail><extent unit="pages"><start>473</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit290"><titleInfo><title>The LNG‐IUS study on adenomyosis: A 3‐year follow‐up study of the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sheng J, Zhang WY, Zhang JP, Lu D. The LNG‐IUS study on adenomyosis: A 3‐year follow‐up study of the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception (2009); 79: 189.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>189</start></extent></part><relatedItem type="host"><titleInfo><title>Contraception</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>189</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit291"><titleInfo><title>St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low‐dose oral contraceptive</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Will‐Shahab L, Bauer S, Kunter U, Roots I, Brattstrom A. St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low‐dose oral contraceptive. Eur J Clin Pharmacol (2009); 65: 287.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>287</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>287</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit292"><titleInfo><title>17. Gastrointestinal System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit293"><titleInfo><title>Acute phosphate nephropathy—comment on Sica et al (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Belsey J. Acute phosphate nephropathy—comment on Sica et al (Letter). Am J Gastroenterol (2008); 103: 800.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>800</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Gastroenterol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>800</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit294"><titleInfo><title>Safety evaluation of Elixir Paregorico® in healthy volunteers: A phase I study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Moraes MEA, Bezerra MM, Bezerra FAF, De Moraes RA, Cavalcanti PP, Uchoa CRA, Lima FAV, De Moraes MO. Safety evaluation of Elixir Paregorico® in healthy volunteers: A phase I study. Hum Exp Toxicol (2008); 27: 751.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>751</start></extent></part><relatedItem type="host"><titleInfo><title>Hum Exp Toxicol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>751</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit295"><titleInfo><title>Pneumocystis jiroveci (carinii) pneumonia following a second infusion of infliximab in a patient with ulcerative colitis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Estrada S, Garcia‐Campos F, Calderon R, Delgado E, Bengoa R, Enciso C. Pneumocystis jiroveci (carinii) pneumonia following a second infusion of infliximab in a patient with ulcerative colitis (Letter). Inflamm Bowel Dis (2009); 15: 315.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>315</start></extent></part><relatedItem type="host"><titleInfo><title>Inflamm Bowel Dis</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>315</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit296"><titleInfo><title>Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SHC. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther (2009); 29: 654.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>654</start></extent></part><relatedItem type="host"><titleInfo><title>Aliment Pharmacol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>654</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit297"><titleInfo><title>Comment: Mesalamine‐associated hypersensitivity myocarditis in ulcerative colitis and the Kounis syndrome (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kounis GN, Kouni SA, Chiladakis JA, Kounis NG. Comment: Mesalamine‐associated hypersensitivity myocarditis in ulcerative colitis and the Kounis syndrome (Letter). Ann Pharmacother (2009); 43: 393.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>393</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>393</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit298"><titleInfo><title>The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Namazi MR. The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine (Editorial). Lupus (2009); 18: 104.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>104</start></extent></part><relatedItem type="host"><titleInfo><title>Lupus</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>104</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit299"><titleInfo><title>Phosphate nephropathy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rex DK. Phosphate nephropathy (Letter). Am J Gastroenterol (2008); 103: 807.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>807</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Gastroenterol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>807</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit300"><titleInfo><title>Meta‐analysis: The efficacy and safety of certolizumab pegol in Crohn's disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shao LM, Chen MY, Chen QY, Cai JT. Meta‐analysis: The efficacy and safety of certolizumab pegol in Crohn's disease. Aliment Pharmacol Ther (2009); 29: 605.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>605</start></extent></part><relatedItem type="host"><titleInfo><title>Aliment Pharmacol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>605</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit301"><titleInfo><title>Thiopurine S‐methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6‐mercaptopurine treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Uchiyama K, Nakamura M, Kubota T, Yamane T, Fujise K, Tajiri H. Thiopurine S‐methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6‐mercaptopurine treatment. J Gastroenterol (2009); 44: 197.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>197</start></extent></part><relatedItem type="host"><titleInfo><title>J Gastroenterol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>197</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit302"><titleInfo><title>18. Anti‐inflammatory Agents ‐ Steroidal</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit303"><titleInfo><title>Repeated peribulbar injections of triamcinolone acetonide: A successful and safe treatment for moderate to severe Graves' ophthalmopathy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bordaberry M, Marques DL, Pereira‐Lima JC, Marcon IM, Schmid H. Repeated peribulbar injections of triamcinolone acetonide: A successful and safe treatment for moderate to severe Graves' ophthalmopathy. Acta Ophthalmol Scand (2009); 87: 58.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>58</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Ophthalmol Scand</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>58</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit304"><titleInfo><title>Steroid‐induced interface fluid syndrome after LASIK (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Moya Calleja T, Iribarne Ferrer Y, Sanz Jorge A, Sedo Fernandez S. Steroid‐induced interface fluid syndrome after LASIK (Letter). J Refract Surg (2009); 25: 235.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>235</start></extent></part><relatedItem type="host"><titleInfo><title>J Refract Surg</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>235</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit305"><titleInfo><title>Randomized, double‐blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Plontke SK, Lowenheim H, Mertens J, Engel C, Meisner C, Weidner A, Zimmermann R, Preyer S, Koitschev A, Zenner HP. Randomized, double‐blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope (2009); 119: 359.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>119</number></detail><extent unit="pages"><start>359</start></extent></part><relatedItem type="host"><titleInfo><title>Laryngoscope</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>119</number></detail><extent unit="pages"><start>359</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit306"><titleInfo><title>19. Teratogens/fetal exposure</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit307"><titleInfo><title>Prolonged neonatal complications after in utero exposure to fluoxetine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alehan F, Saygi S, Tarcan A, Gurakan B. Prolonged neonatal complications after in utero exposure to fluoxetine. J Matern Fetal Neonatal Med (2008); 21: 921.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>921</start></extent></part><relatedItem type="host"><titleInfo><title>J Matern Fetal Neonatal Med</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>921</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit308"><titleInfo><title>Exposition to anti‐TNF drugs during pregnancy: Outcome of 15 cases and review of the literature</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Berthelot JM, De Bandt M, Goupille P, Solau‐Gervais E, Liote F, Goeb V, Azais I, Martin A, Pallot‐Prades B, Maugars Y, Mariette X. Exposition to anti‐TNF drugs during pregnancy: Outcome of 15 cases and review of the literature. Joint Bone Spine (2009); 76: 28.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>28</start></extent></part><relatedItem type="host"><titleInfo><title>Joint Bone Spine</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>28</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit309"><titleInfo><title>Unilateral radius aplasia due to lamotrigine and oxcarbazepine use in pregnancy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cetinkaya M, Ozkan H, Koksal N. Unilateral radius aplasia due to lamotrigine and oxcarbazepine use in pregnancy. J Matern Fetal Neonatal Med (2008); 21: 927.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>927</start></extent></part><relatedItem type="host"><titleInfo><title>J Matern Fetal Neonatal Med</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>927</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit310"><titleInfo><title>Drug use in pregnancy‐physicians' evaluation of quality and clinical impact of drug information centres</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Frost Widnes SKF, Schjott J. Drug use in pregnancy‐physicians' evaluation of quality and clinical impact of drug information centres. Eur J Clin Pharmacol (2009); 65: 303.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>303</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>303</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit311"><titleInfo><title>Suggestions for effective contraception in isotretinoin therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kanelleas AI, Thornton S, Berth‐Jones J. Suggestions for effective contraception in isotretinoin therapy (Letter). Br J Clin Pharmacol (2009); 67: 137.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>137</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>137</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit312"><titleInfo><title>Antenatal steroid therapy for fetal lung maturation: Is there an association with childhood asthma?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pole J, Mustard C, To T, Beyene J, Allen A. Antenatal steroid therapy for fetal lung maturation: Is there an association with childhood asthma?. J Asthma (2009); 46: 47.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>47</start></extent></part><relatedItem type="host"><titleInfo><title>J Asthma</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>47</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit313"><titleInfo><title>Selective serotonin reuptake inhibitor use and risk of gestational hypertension</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernandez‐Diaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry (2009); 166: 320.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>320</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>320</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit314"><titleInfo><title>Use of povidone‐iodine during the first trimester of pregnancy: A correct practice?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Velasco I, Naranjo S, Lopez‐Pedrera C, Garriga MJ, Garcia‐Fuentes E, Soriguer F. Use of povidone‐iodine during the first trimester of pregnancy: A correct practice?. BJOG (2009); 116: 452.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>452</start></extent></part><relatedItem type="host"><titleInfo><title>BJOG</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>452</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit315"><titleInfo><title>The behavioral consequences of exposure to antiepileptic drugs in utero</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vinten J, Bromley RL, Taylor J, Adab N, Kini U, Baker GA. The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav (2009); 14: 197.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>197</start></extent></part><relatedItem type="host"><titleInfo><title>Epilepsy Behav</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>197</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit316"><titleInfo><title>Maternal vasoactive exposures, amniotic bands, and terminal transverse limb defects</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Werler MM, Bosco JLF, Shapira SK. Maternal vasoactive exposures, amniotic bands, and terminal transverse limb defects. Birth Defects Res A Clin Mol Teratol (2009); 85: 52.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>52</start></extent></part><relatedItem type="host"><titleInfo><title>Birth Defects Res A Clin Mol Teratol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>52</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit317"><titleInfo><title>Parsing risk for the use of selective serotonin reuptake inhibitors in pregnancy (Editorial comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yonkers KA. Parsing risk for the use of selective serotonin reuptake inhibitors in pregnancy (Editorial comment). Am J Psychiatry (2009); 166: 268.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>268</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>268</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit318"><titleInfo><title>20. Antidiabetic Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit319"><titleInfo><title>Tolerability outcomes of a multicenter, observational, open‐label, drug‐surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JYC. Tolerability outcomes of a multicenter, observational, open‐label, drug‐surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. Clin Ther (2009); 31: 74.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>74</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>74</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit320"><titleInfo><title>Detemir insulin‐induced anaphylaxis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Perez E, Gonzalez R, Martinez J, Iglesias J, Matheu V. Detemir insulin‐induced anaphylaxis (Letter). Ann Allergy Asthma Immunol (2009); 102: 174.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>174</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Allergy Asthma Immunol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>174</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit321"><titleInfo><title>Do thiazide diuretics alter the pharmocokinetics of metformin in patients with type 2 diabetes already established on metformin? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sung EYY, Moore MP, Lunt H, Doogue M, Zhang M, Begg EJ. Do thiazide diuretics alter the pharmocokinetics of metformin in patients with type 2 diabetes already established on metformin? (Letter). Br J Clin Pharmacol (2009); 67: 130.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>130</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>130</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit322"><titleInfo><title>21. Contrast Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit323"><titleInfo><title>Anaphylaxis to amidotrizoate proved by skin testing and flow cytometry‐based basophil activation test</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dewachter P, Nicaise‐Roland P, Kalaboka S, Lefevre J, Chollet‐Martin S. Anaphylaxis to amidotrizoate proved by skin testing and flow cytometry‐based basophil activation test. Allergy (2009); 64: 501.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>501</start></extent></part><relatedItem type="host"><titleInfo><title>Allergy</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>501</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit324"><titleInfo><title>Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hope TA, Herfkens RJ, Denianke KS, LeBoit PE, Hung YY, Weil E. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol (2009); 44: 135.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>135</start></extent></part><relatedItem type="host"><titleInfo><title>Invest Radiol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>135</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit325"><titleInfo><title>22. Bone Conservation Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit326"><titleInfo><title>Bisphosphonate related osteonecrosis of the jaws (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Campisi G, Fedele S, Colella G, Lo Casto A, Fusco V. Bisphosphonate related osteonecrosis of the jaws (Letter). J Rheumatol (2009); 36: 451.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>451</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>451</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit327"><titleInfo><title>Avascular osteonecrosis of the mandible following bisphosphonate therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chandra PA, Chandra AB, Todd GK. Avascular osteonecrosis of the mandible following bisphosphonate therapy. Am J Ther (2009); 16: 65.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>65</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>65</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit328"><titleInfo><title>Bisphosphonate related osteonecrosis of the jaws (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fung E. Bisphosphonate related osteonecrosis of the jaws (Letter). J Rheumatol (2009); 36: 450.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>450</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>450</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit329"><titleInfo><title>Bisphosphonate related osteonecrosis of the jaws (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Khan A, Hanley DA, Peters E. Bisphosphonate related osteonecrosis of the jaws (Reply). J Rheumatol (2009); 36: 453.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>453</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>453</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit330"><titleInfo><title>Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Miura N, Mizuno N, Aoyama R, Kitagawa W, Yamada H, Nishikawa K, Imai H. Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis. Clin Exp Nephrol (2009); 13: 85.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>85</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Nephrol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>85</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit331"><titleInfo><title>Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long‐term nonsteroidal antiinflammatory drug therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Miyake K, Kusunoki M, Shinji Y, Shindo T, Kawagoe T, Futagami S, Gudis K, Tsukui T, Nakajima A, Sakamoto C. Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long‐term nonsteroidal antiinflammatory drug therapy. J Gastroenterol (2009); 44: 113.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>113</start></extent></part><relatedItem type="host"><titleInfo><title>J Gastroenterol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>113</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit332"><titleInfo><title>Bisphosphonate‐related osteonecrosis of the jaw and its associated risk factors: A Belgium Case Series</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Saussez S, Javadian R, Hupin C, Magremanne M, Chantrain G, Loeb I, Decaestecker C. Bisphosphonate‐related osteonecrosis of the jaw and its associated risk factors: A Belgium Case Series. Laryngoscope (2009); 119: 323.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>119</number></detail><extent unit="pages"><start>323</start></extent></part><relatedItem type="host"><titleInfo><title>Laryngoscope</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>119</number></detail><extent unit="pages"><start>323</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit333"><titleInfo><title>Incidence and risk factors of bisphosphonate‐associated osteonecrosis of the jaws</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stumpe MR, Chandra RK, Yunus F, Samant S. Incidence and risk factors of bisphosphonate‐associated osteonecrosis of the jaws. Head Neck J (2009); 31: 202.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>202</start></extent></part><relatedItem type="host"><titleInfo><title>Head Neck J</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>202</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit334"><titleInfo><title>23. Others</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit335"><titleInfo><title>Pilot safety study of low‐dose vasopressin in non‐septic critically ill children</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baldasso E, Garcia P, Piva J, Branco R, Tasker R. Pilot safety study of low‐dose vasopressin in non‐septic critically ill children. Intensive Care Med (2009); 35: 355.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>355</start></extent></part><relatedItem type="host"><titleInfo><title>Intensive Care Med</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>355</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit336"><titleInfo><title>A randomized, double‐blind, placebo‐controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chonchol M, Locatelli F, Abboud HE, Chatytan C, De Francisco ALM, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA. A randomized, double‐blind, placebo‐controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis (2009); 53: 197.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>197</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Kidney Dis</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>197</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit337"><titleInfo><title>Melanoma during latanoprost therapy: Three cases (Letter) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Esteve E, Beau‐Salinas F, Esteve L, Lemacon JM, Autret‐Leca E, Le Louet H, Hocine R, Wolkenstein P, Plaquet JL. Melanoma during latanoprost therapy: Three cases (Letter) (French). Ann Dermatol Venereol (2009); 136: 60.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>136</number></detail><extent unit="pages"><start>60</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Dermatol Venereol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>136</number></detail><extent unit="pages"><start>60</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit338"><titleInfo><title>Indigo carmine‐induced polymorphic supraventricular bigeminy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fujii T, Yoshinuma H, Kobayashi O. Indigo carmine‐induced polymorphic supraventricular bigeminy (Letter). Acta Anaesthesiol Scand (2009); 53: 417.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>417</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Anaesthesiol Scand</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>417</start></extent></part></relatedItem></relatedItem><identifier type="istex">D9DDB40CD540E03ED72C36319DCB2DB3F7123960</identifier><identifier type="ark">ark:/67375/WNG-Z4H8CGGW-Z</identifier><identifier type="DOI">10.1002/pds.1651</identifier><identifier type="ArticleID">PDS1651</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 John Wiley & Sons, Ltd.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-Z4H8CGGW-Z/record.json</uri></json:item></metadata><author></author><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000830 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000830 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:D9DDB40CD540E03ED72C36319DCB2DB3F7123960
|texte= Current awareness: Pharmacoepidemiology and drug safety
}}
| This area was generated with Dilib version V0.6.33. |  |